

DAVID MARK BROWN MD FACS

dmbmd@retinaconsultantstexas.com

www.retinaconsultantstexas.com

Academic Administrator: Madison Tebo

dmbadmin@retinaconsultantstexas.com

Phone: 713-394-7520

Retina Consultants of Texas, an RCA Company

Physician Partner & Director of Research

1995-Present

Newcastle Office (Main Office & Research Office)

4460 Bissonnet Street, Suite 200, Bellaire, Texas 77401

The Woodlands Office (Research Office)

17350 St. Luke's Way, Suite 120, The Woodlands, Texas 77384

Kingwood Office (Research Office)

350 Kingwood Medical Drive, Suite 200, Kingwood, Texas 77339

Katy Office (Research Office)

23501 Cinco Ranch Boulevard, Suite G205, Katy, TX 77494

Memorial Office (Research Office)

10100 Katy Freeway, Suite 100, Houston, TX 77043

Peakwood Office (Research Office)

800 Peakwood Drive, Suite 1C, Houston, TX 77090

Sugar Land Office (Research Office)

6921 Brisbane Court, Suite 200, Sugar Land, TX 77479

Space Center/Pasadena

11460 Space Center Boulevard., Suite 2, Houston, TX 77059

Northwest Office

21216 NW Freeway, Suite 630, Cypress, TX 77429

Brenham TX Office

2620 Hwy 36 South, Brenham, TX 77833

Lufkin TX Office

2906 Brentwood Drive, Suite 300, Lufkin, TX 75901

San Antonio TX Offices (Research offices)

9480 Huebner Road, Suite 310, San Antonio, TX 78240

10439 State Highway 151, San Antonio, TX 78251

Beaumont TX Office (Research Office)

87 Interstate North, Suite 103, Beaumont, TX 77707

BOARD CERTIFICATION

**Diplomat, American Board of Ophthalmology 1994
ABO Recertification (2005-2014) & (2015-2024)**

LICENSURE

**Texas License #H5425
DEA#: BB1702213**

EDUCATION & TRAINING

1993-1995 **University of Iowa Hospitals & Clinics**
Medical Retina & Vitreoretinal Surgery Fellowship
1990-1993 **University of Iowa Hospitals & Clinics**
Ophthalmology Residency
1989-1990 **Baylor College of Medicine**
Medical/Surgical Internship
1984-1988 **Baylor College of Medicine**
Doctorate of Medicine with "High Honors"
1981-1984 **Houston Baptist University**
Bachelor of Science summa cum laude (4.0/4.0 GPA)

ACADEMIC APPOINTMENTS

**Clinical Professor of Ophthalmology, Department of Ophthalmology
Baylor College of Medicine, Houston, Texas**
**Vice-Chair of Ophthalmology for Research, Department of Ophthalmology,
The Methodist Hospital, Weill Cornell College of Medicine, Houston, Texas**
**Associate Clinical Professor of Ophthalmology, The Methodist Hospital,
Weill Cornell Medical College, Houston, Texas**
**NASA- Research and Clinical Advisory Panel-Space Associated Neuro-ophthalmic Syndrome
NASA Johnson Space Center, Houston, Texas**

ACADEMIC & RESEARCH HONORS

American Society of Retina Specialists (ASRS) Presidential Honor Award 2023
American Academy of Ophthalmology Senior Achievement Award 2014
American Society of Retina Specialists (ASRS) Senior Honor Award 2010
American Society of Retina Specialists (ASRS) Honor Award 2008
Academy of Ophthalmology Honor Award 2000
Heed-Knapp Ophthalmic Foundation Fellowship 1994-1995
Ronald G. Michels Foundation Fellowship Award 1994
(presented to most outstanding U.S. Retina fellow)
Heed Ophthalmic Foundation Thomas Heed Fellowship 1993-1994
PJ Leinfelder Award (most outstanding research in residency) 1991-1992

ELECTED HONORARY SOCIETIES & LISTS

Club Jules Gonin Society (2018)
RETINA HALL OF FAME (charter inductee- 2017)

David M. Brown MD FACS
Page 2

Texas Monthly "Super Doc" (2009-2023)
"Best Doctors In America" (2007-2023)
Macula Society (2008-present)
Retina Society (2006-present)
Ronald G. Michels Fellowship Society (1994)
Society of Thomas Heed Fellows (1993)
Alpha Omega Alpha Medical Honor Society (1985)

PROFESSIONAL ORGANIZATIONS & SOCIETIES

Fellow, American Academy of Ophthalmology
Diplomate, American Board of Ophthalmology
Harris County Ophthalmology Society
Harris County Medical Society
Iowa Eye Association
Fellow, American College of Surgeons
Association for Research in Vision (ARVO)
American Society of Retina Specialists
American Society of Cataract & Refractive Surgery
American Diabetes Association
Juvenile Diabetes Research Foundation
Texas Ophthalmologic Association
American Medical Association

PROFESSIONAL ORGANIZATIONS & SOCIETIES- LEADERSHIP ROLES

Retina Society- Audit Committee Chair (2022-present)
American Society of Retina Specialists - Board of Directors 2014-2021
American Society of Retina Specialists - Practice Management Chair 2014-17
American Society of Retina Specialists – Governmental Affairs 2017-2020
The Foundation of the ASRS- Board of Directors 2014-2021
Macula Society - Credentials Committee 2013-2017
Retina Society- Chair, Audit Committee- 2022- present
Retina Society- Finance Committee- 2018-2020
Retina Society - Nominating Committee Chairman 2013-15
Retina Society - Nominating Committee 2011-15
American Society of Cataract & Refractive Surgery- Retina Clinical Committee 2015-present
Methodist Research Institute - Internal Advisory Committee 2004-2012
Diabetic Retinopathy Clinical Research Network - Executive Committee 2005-2007
Diabetic Research Clinical Network (DRCR) - Planning Committee 2004-2005
Methodist Hospital Research Institute SPRINT - Planning Committee 2003-2004
Harris County Ophthalmology Society - President 2002-2003
Harris County Ophthalmology Society - Executive Committee 1997-2003
Iowa Eye Association - President 2002-2003
University of Iowa Center for Macular Degeneration - Advisory Board 2003-present
Juvenile Diabetes Research Foundation - Board of Directors 1998-2002
Houston American Diabetes Association - Medical Advisory Board 2000-2002
Houston Area American Diabetes Association - Board of Directors 1998-2001

David M. Brown MD FACS

Page 3

PEER REVIEWER

American Journal of Ophthalmology
Archives of Ophthalmology
British Journal of Ophthalmology
EYE
New England Journal of Medicine
OPHTHALMOLOGY
RETINA, The Journal of Retina & Vitreous Diseases
RETINA, Cases & Brief Reports

GOOGLE SCHOLAR | EXPERTSCAPE RANKINGS

h-Index: 45 i10 Index: 74 Citations: 21,892
Expertscape rankings: -based on Pubmed publications past 10 years (www.expertscape.com)
Retinal Vein Occlusion: #3 worldwide, #1 Texas
Macular Degeneration: #13 worldwide, #5 US, #1 Texas
Diabetic Retinopathy: Top 30 worldwide, #1 Texas

PUB-MED INDEXED ORIGINAL PAPERS- AUTHOR

-Wyckoff CC, **Brown DM**, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, Abraham P, Fein JG, Chu KW, Clark WL, Leal S, Schmelter T, Hirshberg B, Yancopoulos GD, Vitti R; CANDELA Study Investigators Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial..JAMA Ophthalmol. 2023 Sep 1;141(9):834-842 PMID: 37535382

-Wyckoff CC, Garweg JG, Regillo C, Souied E, Wolf S, Dhoot DS, Agostini HT, Chang A, Laude A, Wachtlin J, Kovacic L, Wang L, Wang Y, Bouillaud E, **Brown DM**. KESTREL and KITE Phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema. Am J Ophthalmol. 2023 Jul 15:S0002-9394. PMID: 37460036

-Peng ET, Parvus MN, Yu HJ, Laswell SM, Pearce WA, Fan KC, Major JC Jr, **Brown DM**, Wyckoff CC, Patel SB. Risk Factors for the Development of Fellow Eye Horseshoe Retinal Tears Following Horseshoe Retinal Tear in the Presenting Eye. Ophthalmic Surg Lasers Imaging Retina. 2023 Jun;54(6):338-345 PMID: 37352399

-Heier JS, Ho AC, Boyer DS, Csaky K, Vitti R, Perlee L, Chu KW, Asmus F, Leal S, Zeitz O, Cheng Y, Schmelter T, **Brown DM**. Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.J Vitreoretin Dis. 2022 Dec 30;7(1):8-15. PMID: 37008402

-Gibson CR, Mader TH, Lipsky W, **Brown DM**, Jennings R, Law J, Sargsyan A, Brunstetter T, Danilichev SN, Maezawa Y. Implantable Collamer Lens Use in a Spaceflight Participant During Short Duration Spaceflight. Aerosp Med Hum Perform. 2023 Jan 1;94(1):48-50. doi: 10.3357/AMHP.6150.2023. PMID: 36757221.

-**Brown DM**, Nowik M, Bouillaud E, Dugel APU; HAWK Extension Study Investigators. HAWK Extension Study: Safety and Efficacy of Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration. Curr Eye Res. 2023 Jan;48(1):44-50. doi: 10.1080/02713683.2022.2096907. Epub 2022 Nov 18. PMID: 36398628.

-Rao AV, Shah AR, Nguyen VT, Pearce W, Wong TP, **Brown DM**, Wyckoff CC, Patel SB. Use of Optical Coherence Tomography in Detecting Retinal Tears in Acute, Symptomatic Posterior Vitreous Detachment. Retina. 2022 Dec 26. doi: 10.1097/IAE.0000000000003718. Epub ahead of print. PMID: 36728866.

David M. Brown MD FACS

Page 4

-Eichenbaum D, **Brown DM**, Ip M, Khanani AM, Figueroa MS, McAllister IL, Laude A, Guruprasad B, Tang S, Gmeiner B, Clemens A, Souied E. Impact of retinal fluid-free months on outcomes in nAMD: a treatment agnostic analysis of the HAWK and HARRIER studies. Retina. 2022 Dec 20. doi: 10.1097/IAE.0000000000003699. Epub ahead of print. PMID: 36705252.

-**Brown DM**, Kowalski MA, Paulus QM, Yu J, Kumar P, Kane MA, Patel JM, Ethier CR, Pardue MT. Altered Structure and Function of Murine Sclera in Form- Deprivation Myopia. Invest Ophthalmol Vis Sci. 2022 Dec 1;63(13):13. doi: 10.1167/iovs.63.13.13. PMID: 36512347; PMCID: PMC9753793.

-Hanna R, **Brown DM**, Brown A, Baldwin K. Measuring atmospheric turbulence along folded paths using a laser-illuminated differential image motion monitor. Appl Opt. 2022 Nov 10;61(32):9646-9653. doi: 10.1364/AO.468597. PMID: 36606905.

-Abraham JR, Wyckoff CC, Arepalli S, Lunasco L, Yu HJ, Martin A, Mugnaini C, Hu M, Reese J, Srivastava SK, **Brown DM**, Ehlers JP. Exploring the angiographic- biologic phenotype in the IMAGINE study: quantitative UWFA and cytokine expression. Br J Ophthalmol. 2022 Oct;106(10):1444-1449. doi: 10.1136/bjophthalmol-2020-318726. Epub 2021 Jun 7. PMID: 34099465; PMCID: PMC8761372.

-Fan W, Fleming A, Hemert JV, Wyckoff CC, **Brown DM**, Robertson G, Wang K, Falavarjani KG, Sadda SR, Ip M. RETINAL VASCULAR BED AREA IN EYES WITH RETINAL VEIN OCCLUSION ON ULTRA-WIDEFIELD FLUORESCIN ANGIOGRAPHY: WAVE Study. Retina. 2022 Oct 1;42(10):1883-1888. doi: 10.1097/IAE.0000000000003549. PMID: 35976232.

-Khanani AM, **Brown DM**, Jaffe GJ, Wyckoff CC, Adiguzel E, Wong R, Meng X, Heier JS; MERLIN Investigators. MERLIN: Phase 3a, Multicenter, Randomized, Double- Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2022 Sep;129(9):974-985. doi: 10.1016/j.optha.2022.04.028. Epub 2022 May 7. PMID: 35537533.

-**Brown DM**, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, Wolf S, Gupta V, Ngah NF, Liew G, Tuli R, Tadayoni R, Dhoot D, Wang L, Bouillaud E, Wang Y, Kovacic L, Guerard N, Garweg JG. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am J Ophthalmol. 2022 Jun; 238:157-172. doi: 10.1016/j.ajo.2022.01.004. Epub 2022 Jan 14. PMID: 35038415.

-**Brown DM**, Boyer DS, Csaky K, Vitti R, Perlee L, Chu KW, Asmus F, Leal S, Zeitz O, Cheng Y, Schmelter T, Heier JS; RUBY Investigators. INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial. Retina. 2022 Jun 1;42(6):1111-1120. doi: 10.1097/IAE.0000000000003441. Epub 2022 Feb 22. PMID: 35234673; PMCID: PMC9112959.

-Ehlers JP, Patel N, Kaiser PK, Heier JS, **Brown DM**, Meng X, Reese J, Lunasco L, Le TK, Hu M, Srivastava SK. The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD. Invest Ophthalmol Vis Sci. 2022 Jun 1;63(6):17. doi: 10.1167/iovs.63.6.17. PMID: 35713892; PMCID: PMC9206498.

-Fan W, Uji A, Wyckoff CC, **Brown DM**, van Hemert J, Falavarjani KG, Wang K, Sadda SR, Ip M. Baseline retinal vascular bed area on ultra-wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to ranibizumab therapy: two-year analysis of the DAVE Study. Eye (Lond). 2022 Mar 24. doi: 10.1038/s41433-021-01777-7. Epub ahead of print. PMID: 35332289.

-Fan W, Nittala MG, Wyckoff CC, **Brown DM**, Uji A, Hemert JV, Fleming A, Robertson G, Sadda SR, Ip M. NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCIN ANGIOGRAPHY: RECOVERY Study. Retina. 2022 Mar 1;42(3):426-433. doi: 10.1097/IAE.0000000000003358. PMID: 34803132.

-Kar SS, Abraham J, Wyckoff CC, Sevgi DD, Lunasco L, **Brown DM**, Srivastava SK, Madabhushi A, Ehlers JP. Computational Imaging Biomarker Correlation with Intraocular Cytokine Expression in Diabetic Macular Edema: Radiomics Insights from the IMAGINE Study. Ophthalmol Sci. 2022 Feb 4;2(2):100123. doi: 10.1016/j.xops.2022.100123. PMID: 36249694; PMCID: PMC9560558.

-**Brown DM**, Hanna RT, Brown AM, Hixson JG, Baldwin KC. Numerical simulation of a large area scintillometer and laser differential image motion monitor. Appl Opt. 2022 Jan 1;61(1):10-21. doi: 10.1364/AO.442064. PMID: 35200796.

David M. Brown MD FACS

Page 5

-Brown DM. Reply. Ophthalmology. 2021 Oct;128(10): e70. doi: 10.1016/j.ophtha.2021.03.039. Epub 2021 May 13. PMID: 33992472.

-Brown DM, Wyckoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, Higgins PM, Singer M, Weinreich DM, Yancopoulos GD, Berliner AJ, Chu K, Reed K, Cheng Y, Vitti R. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021 Sep 1;139(9):946-955. doi: 10.1001/jamaophthalmol.2021.2809. PMID: 34351414; PMCID: PMC8343518.

-Spaide RF, Gemmy Cheung CM, Matsumoto H, Kishi S, Boon CJF, van Dijk EHC, Mauget-Faysse M, Behar-Cohen F, Hartnett ME, Sivaprasad S, Iida T, Brown DM, Chhablani J, Maloca PM. Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res. 2022 Jan;86:100973. doi: 10.1016/j.preteyeres.2021.100973. Epub 2021 May 21. PMID: 34029721.

-Heier JS, Brown DM, Shah SP, Saroj N, Dang S, Waheed NK, Wyckoff CC, Prenner JL, Boyer DS. Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial. JAMA Ophthalmol. 2021 May 1;139(5):542-547. doi: 10.1001/jamaophthalmol.2021.0221. PMID: 33734306; PMCID: PMC7974836.

-Ehlers JP, Zahid R, Kaiser PK, Heier JS, Brown DM, Meng X, Reese J, Le TK, Lunasco L, Hu M, Srivastava SK. Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2021 Dec;5(12):1204-1213. doi: 10.1016/j.oret.2021.02.012. Epub 2021 Feb 26. PMID: 33640493; PMCID: PMC8387490.

-Abraham JR, Wyckoff CC, Arepalli S, Lunasco L, Yu HJ, Hu M, Reese J, Srivastava SK, Brown DM, Ehlers JP. Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study. Am J Ophthalmol. 2020 Sep 5; 222:328-339. PMID: 32896498.

-Fan W, Uji A, Wang K, Falavarjani KG, Wyckoff CC, Brown DM, Van Hemert J, Sagong M, Sadda SR, Ip M. Severity of Diabetic Macular Edema Correlates with Retinal Vascular Bed Area on Ultra-Wide Field Fluorescein Angiography: DAVE Study. Retina. 2020 Jun;40(6):1029-1037 PMID: 31356494.

-Yu HJ, Kaiser PK, Zamora D, Bocanegra M, Cone C, Brown DM, Sadda SR, Wyckoff CC. Visual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials. Ophthalmol Retina. 2020 Apr 23; S2468-6530(20)30154-8. PMID: 32595096.

-Payne JF, Wyckoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. Br J Ophthalmol. 2020 Apr 17; bjophthalmol-2020-316176. PMID: 32303499.

-Major JC Jr, Lampen SIR, Wyckoff CC, Ou WC, Brown DM, Wong TP, Shah AR. The Texas Taco Technique For Internal Limiting Membrane Flap In Large Full-Thickness Macular Holes: A Short-Term Pilot Study. Retina. 2020 Mar;40(3):552-556. PMID: 30608347.

-Zhou B, Mitchell TC, Rusakevich AM, Brown DM, Wyckoff CC. Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up. Am J Ophthalmol. 2020 Feb; 210:86-96. Epub 2019 Oct 21. PMID: 31647931.

-Heier JS, Wyckoff CC, Waheed NK, Kitchens JW, Patel SS, Vitti R, Perlee L, Chu KW, Leal S, Asmus F, Son V, Schmelter T, Brown DM. Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial. Ophthalmology. 2020 Feb;127(2):211-220. Epub 2019 Sep 25. PMID: 31791663.

-Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, Wyckoff CC, Singerman LJ, Abraham P, Grassmann F, Nuernberg P, Weber BHF, Deschatelets P, Kim RY, Chung CY, Ribeiro RM, Hamdani M, Rosenfeld PJ, Boyer DS, Slakter JS, Francois CG. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 Feb;127(2):186-195. Epub 2019 Jul 16. PMID: 31474439.

David M. Brown MD FACS

Page 6

-Fan W, Nittala MG, Fleming A, Robertson G, Uji A, Wykoff CC, **Brown DM**, van Hemert J, Ip M, Wang K, Falavarjani KG, Singer M, Sagong M, Sadda SR. Relationship Between Retinal Fractal Dimension and Nonperfusion in Diabetic Retinopathy on Ultrawide-Field Fluorescein Angiography. **Am J Ophthalmol.** 2020 Jan; 209:99-106. Epub 2019 Aug 29. PMID: 31472160.

-Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, **Brown DM**, Gomes AV, Warburton J, Weichselberger A, Holz FG; HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. **Ophthalmology.** 2020 Jan;127(1):72-84. Epub 2019 Apr 12. PMID: 30986442.

-Wykoff CC, Nittala MG, Zhou B, Fan W, Velaga SB, Lampen SIR, Rusakevich AM, Ehlers JP, Babiuch A, **Brown DM**, Ip MS, Sadda SR; Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy Study Group. Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial. **Ophthalmol Retina.** 2019 Dec;3(12):1076-1086. Epub 2019 Jul 24. PMID: 31542339.

-Ehlers JP, Uchida A, Hu M, Figueiredo N, Kaiser PK, Heier JS, **Brown DM**, Boyer DS, Do DV, Gibson A, Saroj N, Srivastava SK. Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index. **Ophthalmol Retina.** 2019 Dec;3(12):1056-1066. Epub 2019 Jul 6. PMID: 31473172.

-Fang M, Fan W, Shi Y, Ip MS, Wykoff CC, Wang K, Falavarjani KG, **Brown DM**, van Hemert J, Sadda SR. Classification of Regions of Nonperfusion on Ultra- widefield Fluorescein Angiography in Patients with Diabetic Macular Edema. **Am J Ophthalmol.** 2019 Oct; 206:74-81. Epub 2019 Apr 6. PMID: 30959003.

-Feltgen N, Ogura Y, Boscia F, Holz FG, Korobelnik JF, **Brown DM**, Heier JS, Stemper B, Rittenhouse KD, Asmus F, Ahlers C, Vittori R, Saroj N, Mitchell P. Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies. **Ophthalmol Retina.** 2019 Jul;3(7):553-560. Epub 2019 Feb 27. PMID: 31277796.

-Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, **Brown DM**; TREX-DME Study Group. Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. **Am J Ophthalmol.** 2019 Jun; 202:91-99. Epub 2019 Feb 14. PMID: 30771333.

-Kim RS, Jain RR, **Brown DM**, Bretana ME, Kegley EN, Singer MA, Aragon AV, Scheffler AC. Elevated Choroidal Thickness and Central Serous Chorioretinopathy in the Fellow Eyes of Patients with Circumscribed Choroidal Hemangioma. **Ocul Oncol Pathol.** 2018 Nov;4(6):375-380. Epub 2018 Apr 20. PMID: 30574490.

-Mitchell P, McAllister I, Larsen M, Staurengi G, Korobelnik JF, Boyer DS, Do DV, **Brown DM**, Katz TA, Berliner A, Vittori R, Zeitz O, Metzger C, Lu C, Holz FG. Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies. **Ophthalmol Retina.** 2018 Oct;2(10):988-996. Epub 2018 Mar 31. PMID: 31047501.

-Lampen SIR, Khurana RN, Noronha G, **Brown DM**, Wykoff CC. Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema. **Ophthalmic Surg Lasers Imaging Retina.** 2018 Sep 1;49(9):692-697. PMID: 30222804.

-Wykoff CC, Khurana RN, Lampen SIR, Noronha G, **Brown DM**, Ou WC, Sadda SR; HULK Study Group. Suprachoroidal Triamcinolone Acetonide for Diabetic Macular Edema: The HULK Trial. **Ophthalmol Retina.** 2018 Aug;2(8):874-877. Epub 2018 May 4. PMID: 31047542.

-Kwon S, Wykoff CC, **Brown DM**, van Hemert J, Fan W, Sadda SR. Changes in retinal ischaemic index correlate with recalcitrant macular oedema in retinal vein occlusion: WAVE study. **Br J Ophthalmol.** 2018 Aug;102(8):1066-1071. Epub 2018 Apr 26. PMID:29699979.

-**Brown DM**, Ou WC, Wong TP, Kim RY, Croft DE, Wykoff CC; DAVE Study Group. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. **Ophthalmology.** 2018 May;125(5):683-690. PMID: 29336896.

-Payne JF, Clark WL, Bruce BB, Wykoff CC, **Brown DM**, Menke BM, Iverson SM, Allen KF, Boyer DS; Treat & Extend Protocol in Patients with Diabetic Macular Edema Study Group. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema. **Ophthalmology.** 2018 May 2. pii: S0161-6420(18)30678-X. PubMed PMID: 29729809.

David M. Brown MD FACS

Page 7

-**Brown DM**, Ou WC, Wong TP, Kim RY, Croft DE, Wykoff CC; DAVE Study Group. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. **Ophthalmology**. 2018 May;125(5):683-690. PubMed PMID: 29336896.

-Wykoff CC, Ou WC, Khurana RN, **Brown DM**, Lloyd Clark W, Boyer DS; ENDURANCE Study Group. Long-term outcomes with as-needed aflibercept in diabetic macular edema: 2-year outcomes of the ENDURANCE extension study. **Br J Ophthalmol**. 2018 May;102(5):631-636. PubMed PMID: 28814412.

-Campochiaro PA, Wykoff CC, **Brown DM**, Boyer DS, Barakat M, Taraborelli D, Noronha G; Tanzanite Study Group. Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study. **Ophthalmol Retina**. 2018 Apr;2(4):320-328. PMID: 31047241.

-Brown DM, Heier JS, Boyer DS, Freund KB, Kaiser P, Kim JE, Sarraf D. Current Best Clinical Practices—Management of Neovascular AMD **J. VitreoRetinal Diseases**. 2017 1(5) 294-297.

-Kwon S, Wykoff CC, **Brown DM**, van Hemert J, Fan W, Sadda SR. Changes in retinal ischaemic index correlate with recalcitrant macular oedema in retinal vein occlusion: WAVE study. **Br J Ophthalmol**. 2018 Apr 26. pii: bjophthalmol-2017-311475. PubMed PMID: 29699979.

-Wykoff CC, Ou WC, Croft DE, Payne JF, **Brown DM**, Clark WL, Abdelfattah NS, Sadda SR; TREX-AMD Study Group. Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. **Br J Ophthalmol**. 2018 Apr;102(4):460-464. PubMed PMID: 28779006.

-**Brown DM**, Wykoff CC. Intravitreal aflibercept for proliferative diabetic retinopathy. **Lancet**. 2017 Nov 11;390(10108):2141. PubMed PMID: 29143753.

-Fan W, Wang K, Ghasemi Falavarjani K, Sagong M, Uji A, Ip M, Wykoff CC, **Brown DM**, van Hemert J, Sadda SR. Distribution of Nonperfusion Area on Ultra-Widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study. **Am J Ophthalmol**. 2017 Aug; 180:110-116. PubMed PMID: 28579062.

-Jackson TL, Boyer DS, **Brown DM**, Chaudhry N, Elman M, Liang C, O'Shaughnessy D, Parsons E, Patel S, Slakter JS, Rosenfeld PJ. Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration: a phase 1 Dose Escalation Study. **JAMA Ophthalmology**. 2017 Jul 1;135(7):761-767. PubMed PMID: 28570723.

-Wykoff CC, Ou WC, Wang R, **Brown DM**, Cone C, Zamora D, Le RT, Sagong M, Wang K, Sadda SR; WAVE Study Group. Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial. **Ophthalmology**. 2017 Jun;124(6):919-921. PMID: 28318636.

-Ou WC, **Brown DM**, Payne JF, Wykoff CC. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. **Am J Ophthalmol**. 2017 May 23. pii: S0002-9394(17)30216-7. PMID: 28549848.

-Wykoff CC, Le RT, Khurana RN, **Brown DM**, Ou WC, Wang R, Clark WL, Boyer DS; ENDURANCE Study Group. Reply. **Am J Ophthalmol**. 2017 May; 177:236-237. PubMed PMID: 28302270.

-Ho AC, Albin TA, **Brown DM**, Boyer DS, Regillo CD, Heier JS. The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good. **JAMA Ophthalmol**. 2017 Mar 1;135(3):268-273. PMID: 28114653.

-Wykoff CC, Le RT, Khurana RN, **Brown DM**, Ou WC, Wang R, Clark WL, Boyer DS; ENDURANCE Study Group. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study. **Am J Ophthalmol**. 2017 Jan; 173:56-63. PMID: 27702624.

-Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, **Brown DM**; TREX-DME Study Group. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. **Ophthalmology**. 2017 Jan;124(1):74-81. PMID: 27836430.

-Wang R, Wykoff CC, **Brown DM**. Granular Hyper-reflective Specks by Spectral Domain Optical Coherence Tomography as a sign of West Nile Virus infection: The Stardust Sign **Retin Cases Brief Rep**. 2016 Fall;10(4):349-53. PMID: 26674277.

David M. Brown MD FACS

Page 8

-Heier JS, Korobelnik JF, **Brown DM**, Schmidt-Erfurth U, Do DV, Midena E, Boyer DS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Vittori R, Berliner AJ, Zeitz O, Metzger C, Holz FG. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. **Ophthalmology**. 2016 Nov;123(11):2376-2385. PMID: 27651226.

-Clark WL, Boyer DS, Heier JS, **Brown DM**, Haller JA, Vittori R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA. Reply. **Ophthalmology**. 2016 Oct;123(10): e60-1. PubMed PMID: 27664917.

- Wang R, Wyckoff CC, Christie L, Croft DE, Major JC Jr, Fish RH, **Brown DM**. Choroidal Neovascularization Secondary to Alexandrite Laser Exposure. **Retina Cases Brief Rep**. 2016 Summer;10(3):244-8. PMID: 26584328.

-Clark WL, Boyer DS, Heier JS, **Brown DM**, Haller JA, Vittori R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. **Ophthalmology**. 2016 Feb;123(2):330-6. Epub 2015 Oct 30. PMID: 26522708.

-Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, **Brown DM**, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA 3rd; American Society of Retina Specialists Anti-VEGF for Diabetic Macular Edema Comparative Effectiveness Panel. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. **JAMA Ophthalmol**. 2016 Jan 1;134(1):95-9. PMID: 26512939.

-Wang R, Wyckoff CC, **Brown DM**. Granular Hyperreflective Specks by Spectral Domain Optical Coherence Tomography as Signs of West Nile Virus Infection: The Stardust Sign. **Retina Cases Brief Rep**. 2015 Dec 13. PMID: 26674277.

-Li AL, Wyckoff CC, Wang R, Chen E, Benz MS, Fish RH, Wong TP, Major JC Jr, **Brown DM**, Scheffler AC, Kim RY, O'Malley RE. Endophthalmitis after Intravitreal Injection-: Role of Prophylactic Topical Ophthalmic Antibiotics. **Retina**. 2015 Dec 11. PMID: 26655622.

-Major JC Jr, Wyckoff CC, Croft DE, Wang R, Mariani AF, Lehmann AE, **Brown DM**. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration. **Can J Ophthalmol**. 2015 Oct;50(5):373-7. Epub 2015 Aug 12. PMID: 26455973.

-Boyer DS, Nguyen QD, **Brown DM**, Basu K, Ehrlich JS; RIDE and RISE Research Group. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials. **Ophthalmology**. 2015 Dec;122(12):2504-2513. Epub 2015 Oct 9. PMID: 26452713.

-**Brown DM**, Wyckoff CC, Croft DE, Wong TP; RAVE Study Group. Reply: To PMID 24914476. **Retina**. 2015 Oct;35(10): e61-3 PMID: 26398558.

-Wyckoff CC, Croft DE, **Brown DM**, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR; TREX-AMD Study Group. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. **Ophthalmology**. 2015 Dec;122(12):2514-22. Epub 2015 Sep 29. PMID: 26391465.

-**Brown DM**, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vittori R, Berliner AJ, Zeitz O, Metzger C, Korobelnik JF. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. **Ophthalmology**. 2015 Oct;122(10):2044-52. Epub 2015 Jul 18. PMID: 26198808.

-Croft DE, Wyckoff CC, van Hemert J, Verhoek M, **Brown DM**. Not All Retina Is Created Equal: Metabolic Quantification of Ultra-Widefield Images. **Ophthalmology**. 2015 Dec;122(12):2580-2. Epub 2015 Jun 26. PMID: 26123089.

-**Brown DM**, Korobelnik JF; VISTA and VIVID study investigators. Intravitreal aflibercept for diabetic macular edema. **Ophthalmology**. 2015 Jun;122(6):e38-9. PMID: 26008916.

-Wyckoff CC, **Brown DM**, Croft DE, Major JC Jr, Wong TP. Progressive Non-Perfusion in Ischemic Central Retinal Vein Occlusion. **RETINA**. 2015 Jan; 35(1): 43-7. PMID: 25102193.

David M. Brown MD FACS

Page 9

-Campochiaro PA, Clark WL, Boyer DS, Heier JS, **Brown DM**, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Haller JA. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: The 24-Week Results of the VIBRANT Study. Ophthalmology. 2015 Mar;122(3):538-44. PMID: 25315663.

-**Brown DM**. Eight Questions with Dr. Puliafito. Ophthalmic Surg Lasers Imaging Retina. 2014 Jul 1;45(4):353-5. PMID: 25037016.

-Croft DE, van Hemert J, Wyckoff CC, Clifton D, Verhoek M, Fleming A, **Brown DM**. Precise montaging and metric quantification of retinal surface area from ultra-widefield fundus photography and fluorescein angiography. Ophthalmic Surg Lasers Imaging Retina. 2014 Jul-Aug 1;45(4):312-7. PMID: 25037013.

-Korobelnik J-F, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FJ, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen NJ, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl NS, Vitti R, Berliner AJ, Zeitz O, Metz C, **Brown DM**. Intravitreal Aflibercept for Diabetic Macula Edema. Ophthalmology. 2014 Nov. 121(11):2247-54. Epub 2014 Jul 8. PMID: 25012934.

-**Brown DM**, Wyckoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle K for the RAVE STUDY GROUP, Ranibizumab in Pre-Proliferative (Ischemic) Central Retinal Vein Occlusion (CRVO): The Rubeosis Anti- VEGF (RAVE) Trial. RETINA. 2014. Sep;34(9):1728-35 PMID: 24914476.

-Heier JS, Clark WL, Boyer DS, **Brown DM**, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014 Jul;121(7):1414-1420. Epub 2014 Mar 27. PMID: 24679444.

-Karth PA, Raja SC, **Brown DM**, Kim JE. Outcomes of Macular Hole Surgeries for Macular Telangiectasia Type 2. RETINA. 2014 May;34(5):907-15. PMID: 24270919.

-Wyckoff CC, **Brown DM**, Maldonado ME, Croft DE. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014 Jul;98(7):951-5. Epub 2014 Feb 11. PMID: 24518078.

-Takakura A, Tessler HH, Goldstein DA, Guex-Crosier Y, Chan CC, **Brown DM**, Thorne JE, Wang R, Cunningham ET Jr. Viral retinitis following intraocular or periocular corticosteroid administration: a case series and comprehensive review of the literature. Ocul Immunol Inflamm. 2014 Jun;22(3):175-82. PMID: 24655372.

-Campochiaro PA, Sophie R, Pearlman J, **Brown DM**, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A; RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014 Jan;121(1):209-19. PMID: 24112944.

-Heier JS, **Brown DM**, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Schmidt-Erfurth U. Author reply: To PMID 23084240. Ophthalmology. 2014 Jan;121(1): e5-e6. PMID: 24536092.

-Major JC, Wyckoff CC, Mariani AF, Chen E, Croft DE, **Brown DM**. Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age related macular degeneration activity. RETINA. 2014 Jan;34(1):48-54. PMID: 23764967.

-Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, **Brown DM**, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS. Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results of the VIEW Studies. Ophthalmology. 2014 Jan;121(1):193-201. Epub 2013 Sep 29. PMID: 24084500.

-Wyckoff CC, **Brown DM**, Croft DE, Wong TP. Two year SAVE (Super-dose anti-VEGF) outcomes: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration. Ophthalmology. 2013 Sep;120(9):1945-1946. PMID: 24001533.

-Mariani AF, Major JC Jr, **Brown DM**, Wyckoff CC, Benz MS, Kegley EN. Purtscher-like retinopathy associated with pemphigus vulgaris. Retin Cases Brief Rep. 2013 Fall;7(4):304-6. PMID: 25383823.

David M. Brown MD FACS

Page 10

-Busbee BG, Ho AC, **Brown DM**, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013 May;120(5):1046-56. PMID: 23352196.

-Campochiaro PA, Channa R, Berger BB, Heier JS, **Brown DM**, Fiedler U, Hepp J, Stumpp MT. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. American Journal Ophthalmology. 2013 Apr;155(4):697-704. PMID: 23218689.

-**Brown DM**, Chen E, Mariani A, Major JC Jr; SAVE Study Group; Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Macular Degeneration-Primary End Point. Ophthalmology. 2013 Feb;120(2):349-54. PMID: 23131717.

-Wyckoff CC, **Brown DM**, Chen E, Major JC, Croft DE, Mariani A, Wong TP. SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina. 2013; 44(2):121-6. PMID: 23510037.

-**Brown DM**, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ; RIDE and RISE Research Group. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials: RISE and RIDE. Ophthalmology. 2013 Oct; 120(10):2013-2022. PMID: 23706949.

-**Brown DM**, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPENICUS study. American Journal Ophthalmology. 2013 Mar;155(3):429-437. PMID: 23218699.

-Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, **Brown DM**, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B, Green K, Kane FE, FAMOUS Study Group. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013 Mar;120(3):583-7. PMID: 23218184.

-**Brown DM**, Nguyen QD, Ehrlich JS; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema. Author reply. Ophthalmology. 2013 Jan;120(1):221-2. PMID: 23283201.

-**Brown DM**, Tuomi L, Shapiro H; For The Pier Study Group. Anatomical Measures as predictors of visual outcomes in ranibizumab-treated eyes with Neovascular Age-Related Macular Degeneration. RETINA. 2013 Jan;33(1):23-34. PMID: 23073338.

-Heier JS, **Brown DM**, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-Related Macular Degeneration. Ophthalmology. 2012 Dec;119(12):2537-48. PMID: 23084240.

-Campochiaro PA, **Brown DM**, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, Reichel E, Soubrane G, Kapik B, Billman K, Kane FE, Green K; FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012 Oct; 119(10):2125-32. PMID: 22727177.

-Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, **Brown DM**, Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, Schmelter T, Sandbrink R, Heier JS, DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012 Aug;119(8):1658-65. PMID: 22537617.

-Boyer D, Heier J, **Brown DM**, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X, Beckmann K, Haller JA. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPENICUS study. Ophthalmology. 2012 May;119(5):1024-32. PMID: 22440275.

-Nguyen QD, **Brown DM***, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012 Apr;119(4):789-801. *Co-First Author PMID: 22330964.

David M. Brown MD FACS

Page 11

-Chen E, Lin MY, Cox J, **Brown DM**. Endophthalmitis after intravitreal injection: the importance of Viridans Streptococci. RETINA. 2011 Sep; 31(8) 1525-33. PMID: 21878800.

-Campochiaro PA, **Brown DM**, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG. Sustained benefits of ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011 Oct; 118:(10) 2041-49. PMID: 21715011.

-**Brown DM**, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY. Sustained benefits of ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011 Aug;118(8):1594-602 PMID: 21684606.

-Zhang K, Hopkins JJ, Heier JS, Birch DG, Halperin LS, Albini TA, **Brown DM**, Jaffe GJ, Tao W, Williams GA. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci USA. 2011 Apr 12; 108(15) 6241-5. PMID: 21444807.

-Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K, **Brown DM** for the CLEAR-IT 2 Investigators. 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing. Ophthalmology. 2011 Jun; 118(6) 1098-1106. PMID: 21640258.

-**Brown DM**, JS Heier, Ciulla T, Ben M, Abraham P, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K, Nguyen QD, CLEAR-IT 2 Investigators. Primary Endpoint Results of a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-Related Macular Degeneration. Ophthalmology. 2011 Jun; 118(6) 1089-97. PMID: 21640257.

-Campochiaro PA, **Brown DM**, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperia S, Gonder J, Kapik B, Billman K, Kane FE, FAME STUDY GROUP. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011 Apr; 118(6) 626-35. PMID: 21459216.

-Heier JS, **Brown DM**, Ciulla T, Abraham P, Bankert JM, Chong S, Daniel PE Jr, Kim IK. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology. 2011 Jan; 118(1) 111-8. PMID: 20678799.

-Chen E, **Brown DM**, Wong TP, Benz MS, Kegley E, Cox J, Fish RH, Kim RY. Lucentis using Visudyne study: determining the threshold-dose fluence of Verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. Clin Ophthalmol. 2010 Oct 5; 5(4) 1073-9. PMID: 20957143.

-Chen E, **Brown DM**, Benz MS, Fish RH, Wong TP, Kim RY, Major JC. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign). Clin Ophthalmol. 2010 Oct 21; 4: 1151-8. PMID: 21060664.

- Campochiaro PA, Hafiz G, Shah SM, Bloom S, **Brown DM**, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B, Green K, Kane F; Famous Study Group. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010 Jul; 117(7) 1393-9. PMID: 20202684.

-Chen E, Benz MS, Fish RH, **Brown DM**, Wong TP, Kim RY, Major JC. Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. Clin Ophthalmol. 2010 Oct 28; 4: 1249-52. PMID: 21151329.

-**Brown DM**, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010 Jun; 117(6) 1124-1133. PMID: 20381871.

-Boyer DS, Heier JS, **Brown DM**, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009 Sep; 116(9) 1731-9. PMID: 19643495.

-Luviano DM, Benz MS, Kim RY, Fish RH, Wong TP, Kegley EN, **Brown DM**. Selected clinical comparisons of spectral domain and time domain optical coherence tomography. Ophthalmic Surg Lasers Imaging. 2009 May-Jun; 40(3) 325-8. PMID: 19485303.

David M. Brown MD FACS

Page 12

-**Brown DM**, Michels M; Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: 2-Year Results of ANCHOR Study. **Ophthalmology**. 2009 Jan; 116(1) 57-65 PMID: 19118696.

-**Brown DM**, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus Verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. **Ophthalmology**. 2009 Jan; 116(1):57-65. PMID: 19118696.

-Smith SV, Benz MS, **Brown DM**. Cystoid Macular Edema due to Albumin-Bound Paclitaxel Therapy. **Archives of Ophthalmology**. 2008 Nov; 126:1605-6. PMID: 19001234.

-Regillo CD, **Brown DM**, Abraham P, Kaiser PK, Mieler WF, Yue H, Ianchulev T, Schnieder S, Shams N. Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 1. **American Journal Ophthalmology**. 2008 Feb; 145:239-248. PMID: 18222192.

-Kaiser PK, **Brown DM**, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya N. Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results. **American Journal Ophthalmology**. 2007 Dec; 144: 850-57. PMID: 17949673.

-**Brown DM**, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. **American Journal Ophthalmology**. 2007 Oct; 144(4):627-37. PMID: 17893015.

-Diabetic Retinopathy Clinical Research Network, Browning DJ, Glassman AR, Aiello LP, Beck RW, **Brown DM**, Fong DS, Bressler NM, Danis RP, Kinyoun JL, Nguyen QD, Bhavsar AR, Gottlieb J, Pieramici DJ, Rauser ME, Apte RS, Lim JJ, Miskala PH. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. **Ophthalmology**. 2007 Mar; 114(3):525-36. PMID: 17123615.

-**Brown DM**, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S for the ANCHOR Study Group. Comparison of Ranibizumab and Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: 1-Year Results of the ANCHOR Study. **New England J Med**. 2006 Oct 5; 355: (14) 1432-1444. PMID: 17021319.

-Rosenfeld PJ, **Brown DM**, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim R for the MARINA Study Group. Ranibizumab for Neovascular Age-Related Macular Degeneration: 2-Year Results of the MARINA Study. **New England J Med**. 2006 Oct 5; 355: (14) 1419-1431. PMID: 17021318.

-**Brown DM**, Beardsley R, Fish RH, Kim RY, Wong TP. Long Term Stability of Circumferential Silicone Sponge Scleral Buckling Elements. **RETINA**. 2006 Jul-Aug; 26: 645-49. PMID: 16829806.

-**Brown DM**, Graemiger RA, Hergersberg M, Schinzel A, Messmer EP, Niemeyer G, Schneeberger SA, Streb LM, Taylor CM, Kimura AE, Weingeist TA, Sheffield VC, Stone, EM. Genetic Linkage of Wagner Disease and Erosive Vitreoretinopathy. **Archives of Ophthalmology**. 1995 May; 113(5):671-5. PMID: 7748141.

-**Brown DM**, Vandenburg K, Kimura AE, Weingeist TA, Sheffield VC, Stone EM. Frameshift mutations in the procollagen II gene in Stickler Syndrome. **Human Molecular Genetics**. 1995 Jan; 4(1):141-142. PMID: 7711727.

-**Brown DM**, Sobol WG, Weingeist TA, Folk J. Retinal arteriolar macroaneurysms- Long Term Visual Outcome. **British Journal of Ophthalmology**. 1994 Jul; 78:534-38. PMID: 7918263.

-Boldt HC, **Brown DM**, McGeorge AJ. Echographic Diagnosis of Retinoschisis Facilitated by Scleral Indentation. **American Journal Ophthalmology**. 1994 Jul 15; 118:123-4. PMID: 8023868.

-**Brown DM**, Weingeist TA, Kimura AE, Stone EM. Erosive vitreoretinopathy- A new clinical entity. **Ophthalmology**. 1994 Apr; 101 (4) 694-704. PMID: 8152765.

-**Brown DM**, Nichols BE, Weingeist TA, Sheffield VC, Kimura AE, Stone EM. Procollagen II mutation in Stickler syndrome. **Archives of Ophthalmology**. 1992 Nov; 110:1589-93. PMID: 1444917.

David M. Brown MD FACS

Page 13

-Brown DM, Kimura AE, Ossoinig KC, Weiner GP. Leukemic optic nerve head infiltration treated with oral trans-retinoic acid. Ophthalmology. 1992 Sep; 99:1434-1437. PMID: 1407980.

-Joos KM, Brown DM, Alward WL. A multilens case. Archives of Ophthalmology. 1991 Oct; 109:1343-1344. PMID: 1929910.

-Brown DM, Boniuk M, Font R. Diffuse malignant melanoma of the iris with metastases. Survey of Ophthalmology. 1990 Mar-Apr; 34:357-364. PMID: 2183381.

-Livesay JJ, Cooley DA, Montero CG, Warriam RK, Brown DM, JM Duncan. Surgical experience in descending thoracic aneurysmectomy with and without adjuncts to avoid ischemia. Annals of Thoracic Surgery. 1985 Jan; 39:37-46. PMID: 3966835.

PUB-MED INDEXED ORIGINAL PAPERS- STUDY GROUP

-Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial. Jpn J Ophthalmol. 2023 May;67(3):264-279. PMID: 36897413

-Xue K, Hua P, Maguire MG, Daniel E, Jaffe GJ, Grunwald JE, Ying GS; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmol Retina. 2023 Jul;7(7):564-572. PMID: 36803692

-Maturi RK, Glassman AR, Josic K, Baker CW, Gerstenblith AT, Jampol LM, Meleth A, Martin DF, Melia M, Punjabi OS, Rofagha S, Salehi-Had H, Stockdale CR, Sun JK; DRCR Retina Network. Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreal Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy. JAMA. 2023 Feb 7;329(5):376-385. doi: 10.1001/jama.2022.25029. PMID: 36749332.

-Broadhead GK, Agrón E, Peprah D, Keenan TDL, Lawler TP, Mares J, Chew EY; AREDs/AREDS2 Investigators. Association of Dietary Nitrate and a Mediterranean Diet With Age-Related Macular Degeneration Among US Adults: The Age-Related Eye Disease Study (AREDS) and AREDS2. JAMA Ophthalmol. 2022 Dec 22. doi: 10.1001/jamaophthalmol.2022.5404. Epub ahead of print. PMID: 36547942.

-Silva PS, Marcus DM, Liu D, Aiello LP, Antoszyk A, Elman M, Friedman S, Glassman AR, Googe JM, Jampol LM, Martin DF, Melia M, Preston CM, Wyckoff CC, Sun JK; DRCR Retina Network. Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time. JAMA Ophthalmol. 2022 Oct 1;140(10):936-945. doi: 10.1001/jamaophthalmol.2022.3130. Erratum in: JAMA Ophthalmol. 2023 Jan 1;141(1):104. PMID: 35980610; PMCID: PMC9389436.

-Marcus DM, Silva PS, Liu D, Aiello LP, Antoszyk A, Elman M, Friedman S, Glassman AR, Googe JM, Jampol LM, Martin DF, Melia M, Preston CM, Wyckoff CC, Sun JK; DRCR Retina Network. Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time. JAMA Ophthalmol. 2022 Oct 1;140(10):946-954. doi: 10.1001/jamaophthalmol.2022.3131. Erratum in: JAMA Ophthalmol. 2022 Nov 17; PMID: 35980608; PMCID: PMC9389433.

-Wyckoff CC, Nittala MG, Villanueva Boone C, Yu HJ, Fan W, Velaga SB, Ehlers JP, Ip MS, Sadda SR; RECOVERY Study Group. Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2022 Jul;6(7):557-566. doi: 10.1016/j.oret.2022.02.013. Epub 2022 Mar 5. PMID: 35257962.

-Chew EY, Clemons TE, Agrón E, Domalpally A, Keenan TDL, Vitale S, Weber C, Smith DC, Christen W; AREDS2 Research Group. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω -3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmol. 2022 Jul 1;140(7):692-698. Doi: 10.1001/jamaophthalmol.2022.1640. PMID: 35653117; PMCID: PMC9164119.

David M. Brown MD FACS

Page 14

-Core JQ, Hua P, Daniel E, Grunwald JE, Jaffe G, Maguire MG, Ying GS; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials. *Br J Ophthalmol*. 2022 Apr 15; bjophthalmol-2021-320665. Doi: 10.1136/bjophthalmol-2021-320665. Epub ahead of print. PMID: 35428655.

-Jain N, Liao A, Garg SJ, Patel SN, Wyckoff CC, Yu HJ, London NJS, Khurana RN, Zacks DN; Macula Society Pentosan Polysulfate Maculopathy Study Group. Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: A Macula Society Collaborative Study. *Ophthalmol Retina*. 2022 Mar;6(3):219-227. Doi: 10.1016/j.oret.2021.07.004. Epub 2021 Jul 21. PMID: 34298229.

-Wyckoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two 15-randomized, double-masked, phase 3 trials. *Lancet*. 2022 Feb 19;399(10326):741-755. Doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. PMID: 35085503.

-Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two 15-randomized, double-masked, phase 3, non-inferiority trials. *Lancet*. 2022 Feb 19;399(10326):729-740. Doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. PMID: 35085502.

-Maguire MG, Liu D, Bressler SB, Friedman SM, Melia M, Stockdale CR, Glassman AR, Sun JK; DRCR Retina Network. Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial. *JAMA Ophthalmol*. 2021 Dec 1;139(12):1266-1273. Doi: 10.1001/jamaophthalmol.2021.4103. PMID: 34673898; PMCID: PMC8532036.

-Yu JJ, Agrón E, Clemons TE, Domalpally A, van Asten F, Keenan TD, Cukras C, Chew EY; Age-Related Eye Disease Study 2 Research Group. Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17. *Ophthalmology*. 2019 Feb;126(2):261-273. Epub 2018 Aug 22. PMID:30142373.

-Keenan TD, Agrón E, Domalpally A, Clemons TE, van Asten F, Wong WT, Danis RG, Sadda S, Rosenfeld PJ, Klein ML, Ratnapriya R, Swaroop A, Ferris FL 3rd, Chew EY; AREDS2 Research Group Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16. *Ophthalmology*. 2018 Dec;125(12):1913-1928. Epub 2018 Jul 27: PMID: 30060980.

-Abdelfattah NS, Hariri AH, Al-Sheikh M, Pitetta S, Ebraheem A, Wyckoff CC, Sadda SR; TREX-AMD Study Group. Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial. *Am J Ophthalmol*. 2018 Aug; 192:84-90. Epub 2018 May 12. PMID:29763612.

-Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, Quaggin S, Wells JA, Wyckoff CC; Diabetic Retinopathy Clinical Research Network. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. *Ophthalmology*. 2018 Jul;125(7):1054-1063. Epub 2018 Mar 7. PMID:29525602.

-Abdelfattah NS, Hariri A, Al-Sheikh M, Pitetta S, Ebraheem A, Wyckoff CC, Sadda SR; TREX-AMD Study Group. Topographic Correspondence of Macular Atrophy with Choroidal Neovascularization in Ranibizumab Treated Eyes of the TREX-AMD Trial. *Am J Ophthalmol*. 2018 May 12. Pii: S0002-9394(18)30218-6. PubMed PMID: 29763612.

-Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, Quaggin S, Wells JA, Wyckoff CC; Diabetic Retinopathy Clinical Research Network. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. *Ophthalmology*. 2018 Mar 7. Pii: S0161-6420(17)32232-7. PubMed PMID: 29525602.

-Abdelfattah NS, Al-Sheikh M, Pitetta S, Mousa A, Sadda SR, Wyckoff CC; Treat-and-Extend Age-Related Macular Degeneration Study Group. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. *Ophthalmology*. 2017 Feb;124(2):215-223. PMID: 27863845.

David M. Brown MD FACS

Page 15

-Chang P, Tan A, Jaffe GJ, Fleckenstein M, Holz, FG, Schmitz-Valckenberg S; GAP Study Group. Analysis of Peripapillary Atrophy in Relation to Macular Geographic Atrophy in Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2016 April; 1;57(4):2277-82. PubMed PMID: 27127925.

-Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016 Apr;123(4):858-64. PubMed PMID: 26778329.

-AREDS2 Research Group., Al-Holou SN, Tucker WR, Agrón E, Clemons TE, Sperduto RD, Ferris FL 3rd, Chew EY. The Association of Statin Use with Cataract Progression and Cataract Surgery: The AREDS2 Report Number 8. Ophthalmology. 2016 Apr;123(4):916-7. PMID: 26686966.

-Holbrook JT, Sugar EA, Burke AE, Vitale AT, Thorne JE, Davis JL, Jabs DA; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. Am J Ophthalmol. 2016 Apr;164:29-36. Epub 2015 Dec 31. PMID: 26748056.

-Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology. 2016 Mar;123(3):609-16. PMID: 26681392.

-Wells JA, Glassman AR, Jampol LM, Aiello LP, Antoszyk AN, Baker CW, Bressler NM, Browning DJ, Connor CG, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW; Diabetic Retinopathy Clinical Research Network. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. JAMA Ophthalmol. 2016 Feb;134(2):127-34. PMID: 26605836.

-Kempen JH, Van Natta ML, Altaweel MM, Dunn JP, Jabs DA, Lightman SL, Thorne JE, Holbrook JT; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial. Am J Ophthalmol. 2015 Dec;160(6):1133-1141. Epub 2015 Sep 18. PMID: 26386159.

-Tomkins-Netzer O, Lightman S, Drye L, Kempen J, Holland GN, Rao NA, Stawell RJ, Vitale A, Jabs DA; Multicenter Uveitis Steroid Treatment Trial Research Group. Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results. Ophthalmology. 2015 Nov;122(11):2351-9. PMID: 26359188.

-Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study. Ophthalmology. 2015 Oct;122(10):1976-86. PMID: 26298718.

-Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, Thorne JE. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. Ophthalmology. 2015 Oct;122(10):1967-75. Epub 2015 Aug 20. PMID: 26298715.

-Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ, Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2015 Sep;122(9):1846-53. PMID: 26143666.

-Kuppermann BD, Goldstein M, Maturi RK, Pollack A, Singer M, Tufail A, Weinberger D, Li XY, Liu CC, Lou J, Whitcup SM; Ozurdex® ERIE Study Group. Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial. Ophthalmologica. 2015;234(1):40-54. Epub 2015 Jun 18. PMID: 26088793.

David M. Brown MD FACS

Page 16

-Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL 3rd, Fine SL, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Comparison of Age-related Macular Degeneration Treatments Trials CATT Research Group. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology. 2015 Feb;122(2):391-398. PMID: 25307130.

-Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015 Mar 26;372(13):1193-203. PMID: 25692915.

-Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Sugar EA, Holbrook JT, Kempen JH, Burke AE, Drye LT, Thorne JE, Louis TA, Jabs DA, Altaweel MM, Frick KD. Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis. Ophthalmology. 2014 Oct;121(10):1855-62. PMID: 24908205.

-Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014 Oct;121(10):1904-14. PMID: 24907062.

-Folgar FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014 Oct;121(10):1956-65. PMID: 24835760.

-Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG; CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014 Jul;158(1):128-135.e10. PMID: 24727261.

-Kozak I, Vaidya V, Van Natta ML, Pak JW, May KP, Thorne JE; Studies of the Ocular Complications of AIDS Research Group. The prevalence and incidence of epiretinal membranes in eyes with inactive extramacular CMV retinitis. Invest Ophthalmol Vis Sci. 2014 Jun 12;55(7):4304-12. PMID: 24925880.

-Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014 May;132(5):521-7. PMID: 24652518.

-Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, Liu CC, Li XY, Hollander DA, Schiffman RM, Whitcup SM; Ozurdex PLACID Study Group. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013 Sep;120(9):1843-51. Epub 2013 May 22. PMID: 23706947

-Kempen JH, Sugar EA, Jaffe GJ, Acharya NR, Dunn JP, Elner SG, Lightman SL, Thorne JE, Vitale AT, Altaweel MM; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema. Ophthalmology. 2013 Sep;120(9):1852-9. PMID: 23706700.

-Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Sep;120(9):1860-70. Epub 2013 May 1. PMID: 23642377.

-Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG; Diabetic Retinopathy Clinical Research Network. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology. 2013 Aug; 131(8):1033-40. PMID: 23807371.

-Friedman DS, Holbrook JT, Ansari H, Alexander J, Burke A, Reed SB, Katz J, Thorne JE, Lightman SL, Kempen JH; MUST Research Group. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology. 2013 Aug;120(8):1571-9. Epub 2013 Apr 16. PMID: 23601801.

David M. Brown MD FACS

Page 17

-Danis RP, Domalpally A, Chew EY, Clemons TE, Armstrong J, SanGiovanni JP, Ferris FL 3rd; AREDS2 Study Group. Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). **Invest Ophthalmol Vis Sci.** 2013 Jul 8; 54(7):4548-54. PMID: 23620429.

-Steinberg JS, Auye J, Jaffe GJ, Fleckenstein M, Holz FG, Schmitz-Valckenberg S; GAP Study Group. Longitudinal analysis of reticular drusen associated with geographic atrophy in age-related macular degeneration. **Invest Ophthalmol Vis Sci.** 2013 Jun 10;54(6):4054-60. PMID: 23633663.

-Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; Comparison of AMD Treatments Trials Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). **Ophthalmology.** 2013 Mar;120(3):593-9. Epub 2013 Jan 18. PMID: 23337555.

-Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. **Ophthalmology.** 2013 Jan;120(1):122-9. Epub 2012 Oct 6. PMID: 23047002.

-Varma R, Bressler NM, Suñer I, Lee P, Dolan CM, Ward J, Colman S, Rubio RG; BRAVO and CRUISE Study Groups. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. **Ophthalmology.** 2012 Oct;119(10):2108-18. PMID: 22817833.

-Sun JK, Qin H, Aiello LP, Melia M, Beck RW, Andreoli CM, Edwards PA, Glassman AR, Pavlica MR; Diabetic Retinopathy Clinical Research Network. Evaluation of visual acuity measurements after autorefraction vs manual refraction in eyes with and without diabetic macular edema. **Arch Ophthalmol.** 2012 Apr; 130(4):470-9. PMID: 22159173.

-Diabetic Retinopathy Clinical Research Network, Bressler NM, Miller KM, Beck RW, Bressler SB, Glassman AR, Kitchens JW, Melia M, Schlossman DK. Observational study of subclinical diabetic macular edema. **Eye.** 2012 Jun; 26(6):833-40. PMID: 22441027.

-Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. **Ophthalmology.** 2012 Jul; 119(7):1388-98. PMID: 22555112.

-CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. **New England J Med.** 2011 May 19; 364(20):1897-908. PMID: 21526923.

-Gangaputra S, Almukhtar T, Glassman AR, Aiello LP, Bressler N, Bressler SB, Danis RP, Davis MD; Diabetic Retinopathy Clinical Research Network. Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus. **Invest Ophthalmol Vis Sci.** 2011 Aug 3; 52(9):6168-73. PMID: 21571677.

-Schmitz-Valckenberg S, Alten F, Steinberg JS, Jaffe GJ, Fleckenstein M, Mukesh BN, Hohman TC, Holz FG; Geographic Atrophy Progression (GAP) Study Group. Reticular drusen associated with geographic atrophy in age-related macular degeneration. **Invest Ophthalmol Vis Sci.** 2011 Aug 24; 52(9):5009-15. PMID: 21498612.

-Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK., Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. **Ophthalmology.** 2010 Jun; 117(6):1064-1077. PMID: 20427088.

-Wroblewski JJ, Wells JA 3rd, Adamis AP, Buggage RR, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Altaweel MM; Pegaptanib in Central Retinal Vein Occlusion Study Group. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. **Arch Ophthalmol.** 2009 Apr; 127(4):374-80. PMID: 19365011.

David M. Brown MD FACS

Page 18

- Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, Wells JA 3rd. Observational Study of the Development of Diabetic Macula Edema Following Panretinal (scatter) Photocoagulation Given 1 or 4 Sitzings. Arch Ophthalmol. 2009 Feb; 127(2):132-40. PMID: 19204228.
- Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H; Diabetic Retinopathy Clinical Research Network Study Group. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. RETINA. 2008 Jan;28(1):36-40. PMID: 18185135.
- Browning DJ, Fraser CM. The predictive value of patient and eye characteristics on the course of subclinical diabetic macular edema. American Journal Ophthalmology. 2008 Jan;145(1):149-154. PMID: 17997393.
- Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008 Sep; 115(9):1447-49. PMID: 18662829.
- Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK; DRCR Network. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. American Journal Ophthalmology. 2008 May; 145(5):894-901. PMID: 18294608.
- Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DJ, Flaxel CJ, Fong DS, Foster WJ, Glassman AR, Hartnett ME, Kollman C, Li HK, Qin H, Scott IU; Diabetic Retinopathy Clinical Research Network Study Group. Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci. 2008 May; 49(5):1745-52. PMID: 18316700.
- Glassman AR, Beck RW, Browning DJ, Danis RP, Kollman C. Comparison of Optical Coherence Tomography Retinal Thickness Measurements in Diabetic Macular Edema with and without Reading Center Manual Grading from a Clinical Trials Perspective. Invest Ophthalmol Vis Sci. 2008 Jun 19. PMID: 18566462.
- Browning DJ, Altaweel MM, Bressler NM, Bressler SB, Scott IU; On behalf of the diabetic retinopathy clinical research network. Diabetic Macular Edema: What Is Focal and What Is Diffuse? American Journal Ophthalmology. 2008 Nov;146(5):649-55, 655. PMID: 18774122.
- Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H; Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology. 2008 Aug; 115(8):1366-71. PMID: 18675696.
- Diabetic Retinopathy Clinical Research Network, Krzystolik MG, Strauber SF, Aiello LP, Beck RW, Berger BB, Bressler NM, Browning DJ, Chambers RB, Danis RP, Davis MD, Glassman AR, Gonzalez VH, Greenberg PB, Gross JG, Kim JE, Kollman C. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology. 2007 Aug; 114(8):1520-5. PMID: 17353052.

BOOK CHAPTERS

- Derham AM, **Brown DM**. Available Anti-Vascular Endothelial Growth Factor Agents. Chapter in Duker JS, Liang MC, eds. **Anti-VEGF Use in Ophthalmology**. SLACK Incorporated, Thorofare, NJ, 2017.
- Brown DM**, Weingeist TA. Disorders of the vitreous and vitreoretinal interface, In K Wright, ed, **Pediatric Ophthalmology**. J.B. Lippincott Co., Philadelphia, PA, 2003.
- Brown DM**, Weingeist TA, Smith RE. Histoplasmosis. Chapter in Gold, DH, Weingeist TA, eds. **Color Atlas of The Eye in Systemic Disease**. Lippincott Williams & Wilkins. 1999.
- Sneed SW, **Brown DM**, Weingeist TA. Stickler Syndrome. Chapter in Gold, DH, Weingeist TA, eds. **Color Atlas of The Eye in Systemic Disease**. Lippincott Williams & Wilkins. 1999.

-Brown, J, Stone EMS, **Brown DM**. Best Disease. Chapter in Guyer et al, ed, **RETINA-VITREOUS-MACULA**. W.B. Saunders Company, 1998.

-**Brown DM**, Smith RE, Weingeist TA. Ocular Histoplasmosis. In Pepose JS, Holland GN, Wilhelmus KF (eds) **Ocular Infection and Immunity**. Mosby Year Book, St. Louis, 1997.

-**Brown DM**, Weingeist TA. Disorders of the vitreous and vitreoretinal interface, In K Wright, F Ellis, M Mets, M Del Monte, E Buckley, E Stone, Eds, **Pediatric Ophthalmology**. J.B. Lippincott Co., Philadelphia, PA, 1994.

-**Brown DM**, Weingeist TA. Disorders of the vitreous and vitreoretinal interface, In K Wright, F Ellis, M Mets, M Del Monte, E Buckley, E Stone, Eds, **Pediatric Ophthalmology**. J.B. Lippincott Co., Philadelphia, PA, 1994.

-**Brown DM**, Weingeist TA. High myopia and related conditions. In Cibis GW, Tongue AC, Stass-Isern ML, Eds. **Decision Making in Pediatric Ophthalmology**, CV Mosby. St. Louis. 1993.

NATIONAL/INTERNATIONAL PRESENTATIONS WITH PUBLISHED ABSTRACTS

-**Brown DM**, 2/18/23 Paper Presentation title: RNFL (Radial Nerve Fiber Layer) Scan PVD (Posterior Vitreous Detachment) Staging and Retina Surgery Implications. Macula Society, Miami, FL.

-Kuppermann BD, Hu A, Barakat M, **Brown DM**, Khurana R, Marcus D, Pearlman J, Wyckoff CC, Ciulla T, 2/18/23 Paper Presentation title: Abstract-Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients with Persistent Activity Following Anti-VEGF Therapy (OASIS, NCT04626128). Macula Society, Miami, FL.

-**Brown DM** 2/11/23 Oral Presentation title: Efficacy and Safety of High-Dose (8.0 mg) Aflibercept of Treatment for Wet AMD: 48-Week Results from PULSAR. Angiogenesis, Exudation, and Degeneration, Virtual Meeting.

-Laude A, Wyckoff CC, Garweg JG, Chang A, Wang Y, **Brown DM**, 11/18/22 Paper Presentation title: Brolucizumab for treatment of diabetic macular edema (DME): 100-week results from the KESTREL and KITE studies. Asia-Pacific Vitreo-Retina Society, Taipei.

-**Brown DM**, 11/16-17/22 Oral presentation title: Exploring the anti-angiogenic era of retinal disease. UK Promotional Meeting Series, London, Manchester, Bristol, Birmingham, UK.

-**Brown DM**, 11/3/22 Oral Presentation title: Intravitreal Aflibercept Injection 8 mg for Diabetic Macular Edema: 48-Week Results from the Phase 2/3 PHOTON Trial. Retina Society, Pasadena, CA.

-**Brown DM**, Moini H, Miller N, Xavier V, Piracha Z, Amer F, Tressler C, 11/3/22 Oral Presentation title: Rates of Reported Intraocular Inflammation Following Intravitreal Aflibercept Vial and Prefilled Syringe Injections. Retina Society, Pasadena, CA.

-Murata T, Regillo CD, **Brown DM**, Souied EH, Wolf S, Garweg JG, Dhoot D, Agostini HT, Chang A, Laude A, Kovacic L, Wang L, Wang Y, Bouillaud E, Wyckoff CC, 10/13/22 Paper Presentation title: Brolucizumab for diabetic macular edema: the KESTREL & KITE studies (100-week). Japanese Ophthalmological Society, Virtual Meeting.

-**Brown DM**, Jaffe GJ, Wyckoff CC, Adiguzel E, Wong R, Meng X, Heier JS, Khanani AM, 9/30/22 Poster presentation title: MERLIN: Two-Year Results From the Phase 3a Trial of Brolucizumab in Participants With nAMD and Persistent Retinal Fluid. American Academy of Ophthalmology, Chicago, IL.

-**Brown DM**, 9/30/22 Oral presentation title: Intravitreal Aflibercept Injection 8 mg for Diabetic Macular Edema: 48-Week Results From the Phase 2/3 PHOTON Trial. American Academy of Ophthalmology, Chicago, IL.

-Chang A, Wyckoff CC, Garweg JG, Regillo CD, Souied EH, Wolf S, Dhoot D, Agostini HT, Laude A, Kovacic L, Wang L, Wang Y, Bouillaud E, **Brown DM**, 9/10/22 Paper Presentation title: Brolucizumab for Treatment of Diabetic Macular Edema (DME): 100-Week Results from the KESTREL and KITE Studies. World Ophthalmology Congress 2022, Virtual Meeting.

-Garweg JG, Wyckoff CC, Regillo CD, Wolf S, Souied EH, Dhoot D, Agostini HT, Laude A, Chang A, Kovacic L, Wang L, Wang Y, Bouillaud E, **Brown DM**, 9/1/22 Paper Presentation title: Brolucizumab for treatment of diabetic macular edema (DME): 100-week results from the KESTREL and KITE studies. EURETINA, Virtual Meeting.

David M. Brown MD FACS

Page 20

-Moshfeghi DM, Lad EM, **Brown DM**, Liu J, Vardi M, Gao A, Sadda S, Holz FG, Jaffe GJ, 9/1/22 Poster Presentation title: Design of a Global Phase 2 Randomized, Placebo-Controlled Trial of the Oral Factor D Inhibitor Danicopan in Geographic Atrophy Secondary to Age-Related Macular Degeneration. EURETINA, Virtual Meeting.

-**Brown DM**, 6/24/22 Oral Presentation title: Higher doses of existing intravitreal drugs can be beneficial in the management of nAMD. Congress on Controversies in Ophthalmology, Virtual Meeting.

-**Brown DM**, 5/2/22 Poster Presentation title: Evaluation of 8 mg Intravitreal aflibercept injection for neovascular age-related macular degeneration: results from the phase 2 CANDELA study. Association for Research in Vision and Ophthalmology, Denver, CO.

-Wyckoff CC, Garweg J, Regillo CD, Wolf S, Souied EH, Dhoot D, Agostini H, Laude A, Chang A, Kovacic L, Wang L, Wang Y, Bouillaud E, **Brown DM**, 5/1-4/22 Oral Presentation title: Brolucizumab for treatment of diabetic macular edema (DME): 100-week results from the KESTREL and KITE studies. Association for Research in Vision and Ophthalmology, Denver, CO.

-**Brown DM**, 4/2/22 Oral Presentation title: OCT Choroidal and Optic Nerve Adaptation in NASA's Long-Term Space Flight Program. Pacific Retina Club 2022, UCLA Meyer and Renee Luskin Conference Center Los Angeles.

-**Brown DM**, 4/2/22 Oral Presentation title: Rates of intraocular inflammation following intravitreal aflibercept vial and prefilled syringe injections. Pacific Retina Club 2022, UCLA Meyer and Renee Luskin Conference Center Los Angeles, CA.

-**Brown DM** 2/11-12/22 Oral Presentation title: High Dose Aflibercept for Neovascular AMD. Angiogenesis, Exudation, and Degeneration, Virtual Meeting.

-**Brown DM**, 11/13/21 Oral Presentation: How to Determine Posterior Vitreous Detachment Status with a 10-sec Retinal Nerve Fibe. American Academy of Ophthalmology Conference, New Orleans, LA.

-**Brown DM**, 10/9/21 Oral Presentation title: 52 Week Kestrel and Kite Results. 2021 ASRS 38th Annual Meeting - American Society of Retina Specialists, San Antonio, TX.

-**Brown DM**, 10/1/21 Imaging Presentation: PVI Staging and Retina Surgery Implications. Retina Society, Ritz Carlton Chicago, IL

-**Brown DM**, 6/3/21 Oral Presentation title: Emerging Gene Therapy Treatment. Kiawah Eye 2021, Kiawah Islands, SC.

-**Brown DM**, 5/1/21 Oral Presentation title: Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies. Association for Research in Vision and Ophthalmology, San Francisco, CA.

-**Brown DM**, Drs. Charles, Hariprasad, and Riemann 4/16/21 Oral Presentation title: Gene Therapy and Sustained-Release Retina Therapies. New Orleans Academy of Ophthalmology, New Orleans, LA.

-**Brown DM**, 4/16/21 Oral Presentation title: OCT for Earth and Space, New Orleans Academy of Ophthalmology, New Orleans, LA.

-**Brown DM**, 4/17/21 Oral Presentation title: New Drugs in the Retina Pipeline – New Drugs Coming to Market 2022, New Orleans Academy of Ophthalmology, New Orleans, LA.

-**Brown DM**, 4/17/21 Oral Presentation title: Update on Diabetic Retina Treatment of DME, PDR, and DR. New Orleans Academy of Ophthalmology, New Orleans, LA.

-**Brown DM**, 4/17/21 Oral Presentation title: Lamellar Hole Associated Epiretinal Proliferation – Surgical Intervention in a Common Entity That is Rarely Identified. New Orleans Academy of Ophthalmology, New Orleans, LA.

-**Brown DM**, 4/17/21 Oral Presentation title: Surgical Management of Optic Nerve Pit. New Orleans Academy of Ophthalmology, New Orleans, LA.

-**Brown DM**, 2/13/21 Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD. CANDELA: High Dose Aflibercept for Neovascular AMD, Virtual Meeting.

David M. Brown MD FACS

Page 21

-Tadayoni R, Nimmerjahn F, **Brown DM**, Figueroa M, Bodaghi B, Alecu I, Tanzer D, Loewenstein A 9/3/20 Oral Presentation title: Investigating adverse events of intraocular inflammation with retinal vasculitis and/or retinal vascular occlusion in patients treated with brolucizumab. EURETINA, Virtual Meeting.

-Yang Y, Regillo CD, Wyckoff CC, Souied E, Holz FG, Dugel PU, Alam J, Murray C, **Brown DM** 9/2/20 Oral Presentation title: Number of Injections and Time to Dry Analysis of Brolucizumab versus Aflibercept in Patients with Neovascular AMD: 96-week Data from HAWK & HARRIER. EURETINA, Virtual Meeting.

-**Brown DM**, Wyckoff CC, Yang Y, Holz FG, Souied E, Dugel PU, Alam J, Murray C, Regillo CD 9/2/20 Oral presentation title: Number of Injections and Time to Dry Analysis of Brolucizumab versus Aflibercept in Patients with Neovascular AMD: 96-week Data from HAWK & HARRIER. Club Jules Gonin, Virtual Meeting.

-Regillo CD, Wyckoff CC, Yang Y, Holz FG, Souied E, Dugel PU, Alam J, Murray C, **Brown DM** 7/26/20 Oral Presentation title: Number of Injections and Time to Dry Analysis of Brolucizumab versus Aflibercept in Patients with Neovascular AMD: 96-week Data from HAWK & HARRIER. American Society Retina Specialists, Virtual Meeting.

-**Brown DM** 2/8/20 Oral presentation title: Do We Need More VEGF Blockade?, Angiogenesis, Miami, FL.

-**Brown DM** 10/11/19 Oral presentation title: When Treating NEO AMD, MF Should Not Be Tolerated-PRO, American Academy of Ophthalmology, San Francisco, CA.

-Souied EH, Regillo CD, **Brown DM**, Holz FG, Tanzer D, Alam J, Dugel PU 9/5/19 Oral Presentation title: Time to dry analysis of brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from the HAWK & HARRIER trials. EURETINA, Paris, France.

-Regillo CD, Holz FR, Souied E, **Brown DM**, Alam J, Dugel PU 7/27/19 Oral Presentation title: Time to dry (T2D) analysis of brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from the HAWK and HARRIER trials. American Society Retina Specialists, Chicago, IL.

-**Brown DM** 4/26/19 Oral Presentation title: Promising Therapeutics for Wet AMD, ARVO, Vancouver, BC, Canada.

-**Brown DM** 4/26/19 Oral Presentation title: Should We Treat Diabetic Retinopathy (NPDR & PDR) with Anti-VEGF Agents, Lasers or No, ARVO, Vancouver, BC, Canada.

-Kaiser P, Tadayoni R, Holz FG, **Brown DM**, Weissgerber G, Alam J, Dugel PU 2/14/19 Oral Presentation title: Brolucizumab versus aflibercept for neovascular AMD: 48-week expanded fluid analyses from the HAWK and HARRIER studies. Macula Society, Bonita Springs, FL.

-**Brown DM** 2/13/19 Oral Presentation title: Intravitreal Aflibercept for Diabetic Retinopathy Severity, Macula Society, Bonita Springs, FL.

-**Brown DM** 2/10/19 Oral Presentation: Gene Therapy for Neovascular AMD: Intravitreal Delivery of 7M8 AAV2 Vectors, Angiogenesis, Miami, FL

-**Brown DM** 10/27/18 Oral Presentation- Apellis Filly- Complement Inhibition for Age Related Macular Degeneration. American Academy of Ophthalmology. Chicago, IL.

-**Brown DM** 10/26/18 Oral Presentation- Age Related Macular Degeneration Expert Case Panel. American Academy of Ophthalmology Subspecialty Day. Chicago, IL.

-**Brown DM** 8/13/18 Oral Presentation: Apellis Filly- Complement Inhibition for Age Related Macular Degeneration. Retina Society. San Francisco, CA.

-**Brown DM** 7/21/18 Oral Presentation: Hawk & Harrier- Primary Outcome Results Brolucizumab for Neovascular AMD. American Society Retina Specialists, Vancouver, BC, Canada

-**Brown DM** 7/13/18 Oral Presentation: Combo Therapy with Intravitreal Nesvacumab and Aflibercept for Neovascular (AMD), Club Jules Gonin Society XXXI meeting, Jersey, Channel Islands.

-**Brown DM** 6/18/18 Oral Presentation: Combo Therapy with Intravitreal Nesvacumab and Aflibercept for Neovascular (AMD), World Ophthalmology Congress, Barcelona, Spain

-**Brown DM** 6/03/18 Oral Presentation: Management of DME in 2018: An Evidence Based Approach. Canadian Ophthalmology Society, Toronto, Ontario, Canada.

-**Brown DM** 6/03/18 Oral Presentation: Advancing the Detection and Management of Diabetic Retinopathy with Multimodal Retina Imaging. Canadian Ophthalmology Society, Toronto, Ontario, Canada.

-**Brown DM** 6/02/18 Oral Presentation: Optimizing Outcomes in AMD. Canadian Ophthalmology Society, Toronto, Ontario, Canada.

- Dugel PU, Lang GE, Razavi S, Weichselberger A, Ogura Y, **Brown DM** 4/30/18 Poster Presentation: Predictability of the 12-week dosing status at Week 48 for patients receiving brolucizumab in HAWK and HARRIER. ARVO, Honolulu HI

-**Brown DM** 4/30/18 Poster Session title: IAI for Moderately Severe to Severe NPDR: The Phase 3 Panorama, ARVO, Honolulu, HI

-**Brown DM** 2/23/18 Oral Presentation title: Combo Therapy with Intravitreal Nesvacumab and Aflibercept for Neovascular (AMD), Macula Society, Beverly Hills, CA

-**Brown DM** 2/10/18 Oral Presentation title: Ang2 Inhibition Combined with Anti-VEGF Suppression (Aflibercept) in DMEs, Angiogenesis, Miami, FL

-**Brown DM** 11/12/17 Oral Presentation title: Clinical Applications of ultra-wide-field Imaging, American Academy of Ophthalmology, New Orleans, LA

-**Brown DM** 10/6/17 Oral Presentation title: Choroid and Optic Nerve Changes Associated with long-Term Space Flight, RETINA SOCIETY, Boston, MA

-**Brown, DM** 8/13/17 Oral Presentation title: Navigated Laser Photocoagulation in Coat's Disease-A-Case Series, American Society Retina Specialists, Boston, MA

-**Brown DM** 6/10/17 Oral Presentation title: Intravitreal Rinucumab+Aflibercept in neovascular Age-related Macular Degeneration (nAMD): the CAPELLA Study, Macula Society, Singapore, Asia

-**Brown DM** 5/8/17 Poster Presentation title: Impact of baseline retinal nonperfusion on best corrected visual acuity in eyes with central retinal vein occlusion: post hoc analyses of COPERNICUS and GALILEO, ARVO, Baltimore, Maryland

-**Brown DM** 2/11/17 Oral Presentation title: Intravitreal Approaches to Retinal Gene Therapy: Results from 2nd Generation Vectors, Angiogenesis, Miami, FL

-**Brown DM** 10/15/16 Oral Presentation title: Suprachoroidal Triamcinolone Acetonide Concomitant with IVT Aflibercept: Phase 2 Retinal Vein Occlusion (RVO) Study Aflibercept: Phase 2 Retinal Vein Occlusion (RVO) Study, AAO, Chicago, IL

-**Brown DM** 10/16/16 Oral Presentation title: Study of Combination Therapy With Nesvacumab and Aflibercept for Neovascular AMD and Diabetic Macular Edema, AAO, Chicago, IL

-**Brown DM** 8/11/16 Oral Presentation title: ASRS Research and Therapeutics (ReST) Committee Symposium: Clinical Trials "Unplugged": Real, Practical Questions and Answers, ASRS, San Francisco, CA

-**Brown DM** 5/4/16 Poster Presentation title: CNV Lesion characteristics as a predictor of visual outcome in wet AMD patients receiving combination therapy of intravitreal anti-VEGF therapy and Squalimine lactate ophthalmic solution, ARVO, Seattle, WA

-**Brown DM** 2/25/16 Oral Presentation title: DAVE Presentation-Targeted PRP for the Treatment of DME, Macula Society, Miami, FL

-**Brown DM** 11/14/15 Oral Presentation title: DAVE: Wide Field Guided PRP for DME - 1 yr Results, AAO, Las Vegas, NV

-**Brown DM** 10/8/15 Oral Presentation title: IAI for DME: 148-week Results from VISTA and VIVID, Retina Society, Paris, France

David M. Brown MD FACS

Page 23

-**Brown DM** 7/12/15 Oral Presentation title: Intravitreal Aflibercept for DME: 148 Week Results from the VISTA trial, ASRS, Vienna, Austria

-**Brown DM** 10/21/14 Paper Session Presentation: Intravitreal Aflibercept Injection for ME due to BRVO-52 week outcome, AAO, Chicago, IL

-**Brown DM** 9/14/14 Oral Presentation Presenting-Intravitreal Aflibercept for DME: 24 month Results from VISTA-DME and VIVID-DME, Retina Society, Philadelphia, PA

-**Brown DM** 8/11/2014 Oral Presentation Ranibizumab PRN for DME: Long Term Open-Label Extension of the Phase 3 RIDE & RISE Trials, ASRS, San Diego, CA

-**Brown DM** 5/4/2014 Paper Session Presentation Title: Intravitreal Aflibercept Injection (IAI) for Diabetic Macular Edema (DME): Primary and Additional Endpoint Results from the 12-Month Phase 3 VISTA-DME and VIVID-DME Studies ARVO, Orlando, FL

-Wykoff CC, Croft D, Chen E, Wong TP, **Brown DM** 5/4/2014 Poster Presentation title: Full Thickness Macular Hole Development After Rhegmatogenous Retinal Detachment Repair ARVO, Orlando, FL

-Croft D, van Hemert J, Wykoff CC, Clifton D, Verhoek M, Fleming A, **Brown DM** 5/4/14 Poster Presentation title: Quantification of Retinal Surface-Area from Montaged Ultra-Widefield Fundus Photography ARVO, Orlando, FL

-Coskey A, **Brown DM**, Hooten C, Kao Leslie, Wykoff CC, Major JC, Scheffler AC 5/4/2014 Poster Presentation title: Ocriplasmin for Vitreomacular Adhesion (VMA) in the Clinical Setting: Rates of VMA Release, Development of Macular Holes, and Visual Outcomes. ARVO, Orlando, FL

-**Brown DM** 4/4/2014 Two-Year Results of the COPERNICUS Study Evaluating Intravitreal Aflibercept Injection, WOC, Tokyo, JP

-**Brown DM** 9/27/2013 Aflibercept for Diabetic Macular Edema- Phase III Primary Endpoint Results of VISTA/VIVID trials, RETINA SOCIETY, Beverly Hills, CA

-**Brown DM**, Wykoff CC. 3/1/2013 Capillary Non-perfusion in Pre-Proliferative (Ischemic) CRVO Treated with Ranibizumab in the RAVE (Rubeosis Anti-VEgf) Trial. Macula Society. Dana Point, CA

-**Brown DM** 11/12/2012 Paper Presentation One- Year Results of the Phase 3 COPERNICUS Study: Intravitreal Aflibercept Injection in Central Vein Occlusion. AAO, Chicago, Illinois

-**Brown DM** 11/11/2012 Paper Presentation title: 36-Month Efficacy and Results of RISE and RIDE, 2 Phase III Randomized Controlled Clinical Trials of Ranibizumab for Diabetic Macular Edema. AAO, Chicago, Illinois

-**Brown DM** 10/7/2012 for the HARBOR Study. Presentation title: Use of Optical Coherence Tomography to Define Dry Status and its Association with Visual Acuity Outcomes after Ranibizumab Treatment. 45th Annual Retina Society Meeting, Washington D.C.

-**Brown DM** 9/8/2012 Paper Presentation title: Intravitreal Aflibercept Injection in Central Retinal Vein Occlusion: Results of the Phase 3 COPERNICUS Study. EURETINA METTING, Milan, Italy

-**Brown DM** 8/27/2012 Paper Presentation title: 36-Month Efficacy and Results of RISE and RIDE, 2 Phase III Randomized Controlled Clinical Trials of Ranibizumab for Diabetic Macular Edema. ASRS, Las Vegas, Nevada

- Mariani AF, Wykoff CC, **Brown DM**, Kegley E 5/9/2012 for the AORTA study. Poster Session title: An Outer Retinal Tubulation Analysis Study. ARVO, Ft. Lauderdale, Florida

-**Brown DM** 5/5/2012 for the COPERNICUS Study. Poster Presentation title: Intravitreal Aflibercept Injection in Central Retinal Vein Occlusion: 1-year Results of the Phase 3. ARVO, Ft. Lauderdale, Florida

-**Brown DM** 2/17/2012 Free Paper Session. Presentation title: Phase 3 COPERNICUS Study of VEGF Trap-Eye in CRVO. World Ophthalmology Congress, Abu Dhabi, United Arab Emirates

David M. Brown MD FACS

Page 24

-**Brown DM** 2/17/2012 Free Paper Session for the RISE and RIDE trial. Presentation title: Two Clinical Trials of Ranibizumab for Diabetic Macular Edema (DME). World Ophthalmology Congress, Abu Dhabi, United Arab Emirates

-**Brown DM** 2/16/2012 Free Paper Session for the SAVE trial. Presentation title: 2.0-mg Intravitreal Ranibizumab for Recalcitrant Neovascular Age-Related Macular Degeneration. World Ophthalmology Congress, Abu Dhabi, United Arab Emirates

-**Brown DM** 10/24/2011 Poster Presentation title: One- Year Results of the VIEW 1 and VIEW 2 Studies: VEGF TRAP-Eye in Wet AMD. AAO, Orlando, Florida

-**Brown DM** 10/24/2011 Alimera Paper Presentation title: A Single 0.2ug/d Fluocinolone Acetonide Injectable Insert Provides Improved Visual Acuity for Up to 36 Months in DME. AAO, Orlando, Florida

-**Brown DM** 8/22/2011 Poster Session title: OCT in the Management of Neovascular AMD: A Comparison of Spectralis-Domain and Time-Domain Retinal Imaging Systems. ASRS, Boston, MA

-**Brown DM** 5/26/2011 Paper Session for the SAVE (Superdose Anti-VEgf) trial. Presentation Title: 2.0-mg Intravitreal Ranibizumab for Recalcitrant Neovascular Age-Related Macular Degeneration. EURETINA, London, England

-**Brown DM**, Nguyen QD, Rubio RG, Gibson A, Hopkins J, Sy J, Rundle AC, Ehrlich JS, RISE/RIDE Study Group 5/3/2011 Ranibizumab for Diabetic Macular Edema (DME): 24-month Efficacy and Safety Results- a Phase 3 Randomized Clinical Trial. LATE-BREAKING Retina Papers, ARVO Sarasota, Florida

-Haller JA, Boyer DS, Heier JS, **Brown DM**, Clark L, Vitti R 5/3/2011 VEGF Trap-Eye in CRVO: Primary Endpoint Results of the Phase 3 Randomized Controlled Trial. LATE-BREAKING Retina Papers, ARVO Sarasota, Florida

-Chen E, Mariani A, **Brown DM** 5/2/2011 SAVE (Superdose Anti-VEgf) Trial- 2.0 mg intravitreal ranibizumab for recalcitrant neovascular age-related macular degeneration. Retina Free Paper Session, ARVO Sarasota, Florida

-**Brown DM** 5/2/2011 How does anti-VEGF treatment compare with sustained delivery of Steroids? AMD Special Interest Group, ARVO Sarasota, Florida

- Patel M, Berger BB, Heier JS, **Brown DM**, Campochiaro P, Stumpp MT 5/1/2011 ARVO Poster: Single Ascending Doses of DARPIn®, MP0112, Show Potential for Quarterly Dosing in DME ARVO Sarasota, Florida

-**Brown DM** 3/21/2011 Presentation title: What to do when our current therapy isn't enough - the SAVE (Superdose Anti-VEGF) Trial: 2.0-mg Intravitreal Ranibizumab for Recalcitrant Neovascular AMD. Asia Pacific Academy of Ophthalmology (APAO meeting) Melbourne, Australia

-**Brown DM** 3/20/2011 Presentation title: The COPERNICUS Study (24-Week Results): VEGF trap-eye for the treatment of macular edema secondary to central retinal vein occlusion. Asia Pacific Academy of Ophthalmology (APAO meeting) Melbourne, Australia

-**Brown DM** for the FAME Study Group. Presentation Title: Alimera Fluocinolone Implant for Diabetic Macular Edema FAME Study 36-Month Endpoint. Macula Society Meeting, Boca Raton, FL

-**Brown DM** 10/18/2010 Poster Session at AAO. Presentation Title: SAVE (Superdose Anti-VEGF) Trial: 2.0-mg Intravitreal Ranibizumab for Recalcitrant Neovascular AMD.

-**Brown DM** 10/16/2010 Presenter: Panel Discussion at AAO Subspecialty Day. Presentation Title: A Panretinal Perspective.

-**Brown DM** 9/25/2010 SAVE (Superdose Anti-VEGF) Trial: 2.0-mg Intravitreal Ranibizumab for Recalcitrant Neovascular AMD Presentation at Retina Society.

-**Brown DM** 9/23/2010 52-Year-Old Woman with Unilateral Cystic Atrophy of the Fovea FFA Case Conference Retina Society.

-**Brown DM** 8/29/2010 Presentation at ASRS 2010 Meeting, Vancouver BC Presentation Title: SAVE (Superdose Anti-VEGF) Trial: 2.0-mg Intravitreal Ranibizumab for Recalcitrant Neovascular AMD

-Major JC, **Brown DM** 5/6/2010 Poster Session at ARVO, Sarasota Florida. DA VINCI: DME and VEGF Trap-Eye: Investigation of Clinical Impact: Phase 2 Study in Patients With Diabetic Macular Edema (DME).

David M. Brown MD FACS

Page 25

-**Brown DM**, Chen E, Benz MS, Fish RH, **Brown DM**, Wong TP, Kim RY, Major JC 5/2/2010: Poster Title: Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. Session at ARVO, Sarasota, Florida

-**Brown DM** 02/25/2010 Paper Presentation at Macula Society Presentation Title: Fluocinolone Acetonide Intravitreal Insert (Iluvien) for Diabetic Macular Edema- Results of the Phase 3 Randomized Controlled Trial

-**Brown DM** 02/20/2010 Paper Presentation at Angiogenesis 2010 Meeting- Bascom Palmer Eye Institute, Miami, FL. Presentation Title: Anti-VEGF Therapy

-**Brown DM** 2009 Best of the Posterior Segment Papers 2009 - Safety and Efficacy of Intravitreal Ranibizumab (LUCENTIS®) in Patients with Macular Edema Secondary to Central Retinal Vein Occlusion: CRUISE Study. AAO San Francisco, California.

-**Brown DM** 11/2009 Retina 2009: The Cutting Edge - Panelist: Case Presentations: Imaging Pearls in Exudative AMD Management. AAO subspecialty day, San Francisco, CA

-**Brown DM** 9/2009 Safety and Efficacy of Intravitreal Ranibizumab (LUCENTIS®) in Patients with Macular Edema Secondary to Central Retinal Vein Occlusion: CRUISE Study. Retina Congress- Combined Retina Society, Macula Society, ASRS Meeting, New York, NY

-**Brown DM** 1/2009 Correlation of Anatomic Qualitative OCT & Visual Acuity in ARMD trials, Macula 2009, New York, NY

-**Brown DM** 11/2008 Anatomic outcomes of Sailor 1 Trial. AAO subspecialty day, Atlanta, GA

-**Brown DM** 10/2008 Neovista Anatomic outcomes of phase II trial with brachiotherapy and intravitreal bevacizumab. ASRS, Maui, Hawaii

-**Brown DM** 9/2008 One Year Results of a Phase 2, Randomized, Controlled Dose- and Interval-Ranging Study of Intravitreal VEGF Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration. Retina Society, Scottsdale, AZ

-**Brown DM** 2008 Anatomic outcomes of PIER trial. Macula Society, Florida

-**Brown DM**, Heier JS 12/2007 Phase II results of Regeneron VEGF-TRAP trial for neovascular AMD. American Society of Retina Specialist, Palm Springs, CA

-**Brown DM**. 12/2007 Angiographic findings in PIER Year 2. American Society of Retina Specialist, Palm Springs, CA

-**Brown DM** 11/2007 Rubeosis Anti-VEgf (RAVE) trial 1 year results (Ranibizumab for ischemic CRVO). AAO Subspecialty Day, New Orleans, LA

-**Brown DM**, Wong TP, Benz MS, Kim RY, Fish RH, Strickler A 2007 Rubeosis Anti-VEGF Ischemic Central Retinal Vein Occlusion. AAO Poster Session, New Orleans, LA

-**Brown DM** 10/2007 Microplasmin for Vitreomacular Traction. Retina Society, Boston, MA

-**Brown DM** 10/2007 Rubeosis Anti-VEgf (RAVE) trial 1 year results (Ranibizumab for ischemic CRVO). Retina Society, Boston, MA

-Wong TP, **Brown DM** 5/2007 Combrestatin for Choroidal Neovascular Membranes Secondary to Pathologic Myopia. Poster Session ARVO

-**Brown DM**, H Yue, N Shams for the PIER Study Group 05/2007 LUCENTIS® (Ranibizumab) in Neovascular Age-Related Macular Degeneration (AMD): Subgroup Analysis of Year 1 PIER Efficacy Data. Poster Session ARVO

-Benz MS, **Brown DM**, Wong TP, Kim RY, Fish RH, Strickler A 5/3/2006 Macular Edema in Ischemic Central Retinal Vein Occlusion Modified by Intravitreal Ranibizumab. Poster Session ARVO

-**Brown DM**, Schapiro H, Schneider S, The Anchor Group 05/02/2006 Subgroup Analysis of First-Year Results of ANCHOR: A Phase III, Double-Masked, Randomized Comparison of Ranibizumab and Verteporfin Photodynamic Therapy for Predominantly Classic Choroidal Neovascularization Related to Age-Related Macular Degeneration. Paper Session ARVO

David M. Brown MD FACS

Page 26

-**Brown DM**, Fong DS for the Diabetic Retinopathy Research Network 9/16/2005 The correlation of OCT-measured retinal thickness and visual acuity in eyes with diabetic macular edema. Retina Society, Coronado, CA

-Kim RY, **Brown DM**, Fish RH, Wong TP 5/01/05 Photodynamic Therapy using Low-Dose Verteporfin in the Treatment of chronic central serous retinopathy. ARVO Poster session

-**Brown DM**, Beardsley R, Fish RH, Kim RY, Wong TP 4/27/2004 Long Term Stability of Circumferential Silicone Sponge Scleral Buckling Elements. ARVO Poster session

-**Brown DM**, Kimura AE, Sebag J, Weingeist TA 1999 Vitreoretinopathy Update & Review. 1999 AAO Instruction course, Senior Instructor David M. Brown, M.D. Orlando, FL

-**Brown DM**, Kimura AE, Sebag J, Weingeist TA. 11/1998 Vitreoretinopathy Update & Review. 1998 AAO Instruction course, Senior Instructor David M. Brown, M.D. New Orleans, LA

-**Brown DM**, Kimura AE, Sebag J, Weingeist TA. 10/1997 Vitreoretinopathy Update & Review. 1997 AAO Instruction course, Senior Instructor David M. Brown, M.D. San Francisco, CA

-**Brown DM**, Kimura AE, Sebag J, Weingeist TA. 10/1996 Vitreoretinopathy Update & Review. 1996 AAO Instruction course, Senior Instructor David M. Brown, M.D. Chicago, IL

-Keenum DG, Boldt HC, **Brown DM**, McGeorge AJ, Folk JC 10/1995 Cystic Macular Holes. Presented AAO poster session. Atlanta, GA

-**Brown DM**, Reddy CV et al. 10/1995 Diabetes Slit Lamp Retinal Laser Course HO-207. AAO Instruction Course, Atlanta, GA

-**Brown DM**, Kimura AE, Sebag J, Weingeist TA. 10/1995 Vitreoretinopathy Update & Review. 1995 AAO Instruction course, Senior Instructor David M. Brown, M.D. Atlanta, GA

-Stone EM, **Brown DM**, Weingeist TA. 2/1995 Genetic Linkage of Wagner Disease and Erosive Vitreoretinopathy. Presented Macula Society

-Keenum D, **Brown DM**, McGeorge AJ, Boldt HC, Folk JC 05/1995 Cystic Macular Holes. Presented ARVO, Fort Lauderdale, FL

-**Brown DM**, Kimura AE, Sebag J, Weingeist TA 11/1994 Vitreoretinopathy Update & Review. 1994 AAO Instruction course, Senior Instructor David M. Brown, M.D. San Francisco, CA

-**Brown DM**, Vandenburg K, Kimura AE, Weingeist TA, Sheffield VC, Stone EM 5/1994 Incidence of frameshift mutations in the procollagen II gene in Stickler Syndrome and report of 4 novel mutations. Investigative Ophthalmology and Visual Science, ARVO Abstract Issue, Presented Sarasota, FL

-McGeorge A, Curtis M, **Brown DM**, Stone EM 5/1994 Long term visual outcome of patients with von-Hippel-Lindau syndrome. Investigative Ophthalmology and Visual Science, ARVO Abstract Issue, Presented Sarasota, FL

-Kimura AE, **Brown DM**, Rummelt V, Folberg F, Stofac RL 11/1993 Recurrent secondary cataracts after Nd:YAG capsulotomies in myotonic dystrophy. Ophthalmology AAO Final Program, 100:(9A)-1041993 AAO meeting, Chicago, IL

-**Brown DM**, Jones TM, Hamill MB. 11/1993 Preoperative predictors of occult scleral rupture. Ophthalmology AAO Final Program, 100:(9A)-144, Presented 1993 AAO meeting- Chicago, IL

-**Brown DM**, Vandenburg K, Nichols BE, Kimura AK, Weingeist TA, Sheffield VC, Stone EM 10/1993 Genetic mutations at the C-terminal end of the procollagen II gene in Stickler syndrome (Hereditary arthro-ophthalmopathy) and identification and phenotypic description of a new mutation. Am. J. Hum. Genetics 53: (supp)-1133, American Society of Human Genetics, New Orleans, LA

-**Brown DM**, Weingeist TA, Kimura AE, Stone EM 11/1992 Erosive vitreoretinopathy- A new clinical entity. Ophthalmology AAO Final Program, 99:9A, 151, Presented 1992 AAO meeting, Dallas, TX

-**Brown DM**, Vandenburg K, Nichols BE, Kimura AE, Sheffield VC, Stone EM 1992 Type II procollagen gene mutation in Stickler syndrome. Am. J. Hum. Genetics 51: supp- A301, American Society of Human Genetics.

David M. Brown MD FACS

Page 27

-**Brown DM**, Sobol WG, Weingeist TA, Folk JC 10/1991 Retinal arteriolar macroaneurysms - Long-term visual outcome. 1991 AAO meeting presentation, Anaheim, CA

-**Brown DM**, Sobol WG, Weingeist TA, Folk J 1991 Laser photocoagulation of retinal arteriolar macroaneurysms. Investigative Ophthalmology and Visual Science 32: ARVO Abstract issue: 194.

-**Brown DM**, Jones TM, Hamill MB 1989 Preoperative predictors of occult scleral rupture, Investigative Ophthalmology and Visual Science 30: ARVO Abstract issue: 195.

-Pinke RS, **Brown DM**, Wilhelmus KR, Osato MS 1988 Wound healing of the ocular surface, Investigative Ophthalmology and Visual Science 29: ARVO Abstract issue: 194.

BASIC SCIENCE FUNDING

2005- Principal Investigator- Methodist Research Institute- \$5,000

Histopathologic and in vivo assessment of VEGF isoforms in age related macular degeneration, diabetic retinopathy, and retinal vein occlusive disease.

1994- Principal Investigator- Knights Templar Eye Foundation- \$20,000

Linkage of Erosive Vitreoretinopathy and Wagner disease published.

1993- Principal Investigator- Knights Templar Eye Foundation- \$20,000

Clinical/genetic study of vitreoretinopathies (retinal detachment syndromes and familial exudative vitreoretinopathy).

1992- Principal Investigator: Knights Templar Eye Foundation- \$20,000

Clinical/genetic study of Stickler syndrome with evaluation of ocular manifestations, radiological findings, orthopedic, and otolaryngology manifestations.

1991- Principal Investigator: Knights Templar of Iowa, Newton, Iowa- \$20,000

Genetic & clinical aspects of Stickler syndrome, retinal detachment syndromes and associated vitreoretinopathies.

HUMAN CLINICAL TRIALS

2023 - Principal & Sub-Investigator - Amgen - An Open Label, Two-Arm Study in Subjects with Choroidretinal Vascular Disease to Evaluate ABP 938 and Aflibercept (Eylea®) in a Prefilled Syringe (Protocol ABP 938 / 20210034)

2023 - Sub-Investigator - Priovant - A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active Non-Infectious Intermediate-, Posterior-, and Panuveitis (Protocol Neptune / PVT-2201-201)

2022 - Sub-Investigator - EyePoint - A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1902, a Tyrosine Kinase Inhibitor (TKI), compared to Sham for the Improvement of Moderately Severe to Severe NPDR (Protocol PAVIA / EYP-1901-204)

2022 - Sub-Investigator - Perceive Biotherapeutics - Phase 1/2a Dose Escalation Safety Study of VOY-101 in Subjects with Advanced Non-Neovascular Age-Related Macular Degeneration (Protocol PBI-AMD-001)

2022 - Sub-Investigator - Curacle - Phase 2a, randomized, open-label, parallel-group study in approximately 60 patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 12 weeks (Protocol CU06-RE-P2A-01)

2022 - Sub-Investigator - Genentech - A Phase I, Multicenter, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7446603 Alone and Co-Administered with Aflibercept in Patients with Diabetic Macular Edema (Protocol Honda | GR43828)

2022 - Sub-Investigator - Lowy Medical Research Institute - Phase 2a Study of the Effect of Serine Supplementation and Fenofibrate Treatment on Serum Deoxysphinganine Levels in Patients with Macular Telangiectasia Type 2 (Protocol SAFE)

David M. Brown MD FACS

Page 28

2022 - Sub-Investigator - Allgenis - A Multicenter, Open-Labeled, Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of Intravitreal Ag-73305 in Patients with DME (Protocol ALL-P2-73305-001)

2022 - Sub-Investigator - Adverum - A Multi-Center, Randomized, Open Label Study of ADV-022 (AAV. 7m8-aflibercept) in Neovascular Age-related Macular Degeneration (Protocol Luna / ADV-022-11)

2022 - Sub-Investigator - Annexin - Dose ascending safety, tolerability, and proof of concept double masked, placebo controlled, randomised study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion (Protocol ANN-004)

2022 - Principal & Sub-Investigator - EyePoint - A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept, in Subjects with Wet AMD (Protocol DAVIO 2 / EYP-1901-201)

2022 - Sub-Investigator - Regenxbio - A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (Protocol Ascent / RGX-314-3101)

2022 - Sub-Investigator - Adverum - A Long-Term Follow-Up Study of ADV-022 in Diabetic Macular Edema-INFINITY Extension (Protocol Infinity Extension / ADV-022-10)

2022 - Principal Investigator - Genentech - A Multicenter, Prospective Observational Study of the Progression of Intermediate Age-Related Macular Degeneration to the Onset of Atrophic AMD (Protocol Honu / GE43220)

2022 - Principal & Sub-Investigator - Oxular - A Multi-Center, Randomized, Two-Arm, Parallel-Group, Single-masked, 24-week, Clinical Trial to Evaluate Safety and Tolerability of Two Dose Levels of Suprachoroidal Triamcinolone Acetonide Administered with the Oxulumis Ophthalmic Administration Device in Subjects with DME (Protocol CAPE / OXUCT-103)

2022 - Sub-Investigator - Novartis - A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration (Protocol CLNP023E12201)

2022 - Sub-Investigator - Bayer - A Phase 2 randomized, placebo-controlled, double-masked proof-of-concept study to investigate the efficacy and safety of runcaciguat (BAY 1101042) in patients with moderately severe to severe non-proliferative diabetic retinopathy (Protocol Neon / 20739)

2022 - Sub-Investigator - Verily Life Sciences - A multicenter study to evaluate the performance of Automated Retinal Disease Assessment software for the detection of more than mild Diabetic Retinopathy (ARDA mtmDR study / 101703)

2022 - Principal & Sub-Investigator - OcuTerra - A Phase 2 Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (Protocol DREAM / OTT-166-201)

2022 - Sub-Investigator - Valo Health - Phase 2 study to evaluate the safety and efficacy of OPL-0401 in patients with Nonproliferative Diabetic Retinopathy (Protocol SPECTRA / OPL-0401-201)

2022 - Sub-Investigator - EyePoint - Phase 4 Study of YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg in the Treatment of Chronic Noninfectious Posterior Segment Uveitis (Protocol Synchronicity / EYP-YUT-002)

2022 - Sub-Investigator - Acelyrin - A Phase 2 Dose-finding Study to Evaluate the Efficacy, Safety, and Immunogenicity of Izokibep in Subjects with With Non-infectious Intermediate Uveitis, Posterior Uveitis or Panuveitis (Protocol 21103)

2022 - Principal Investigator - AffaMed Therapeutics - A Prospective, Multi-Center, Open-label, Sequential, Multiple Ascending-Dose and Randomized Dose-Expansion Cohorts Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AM712 Following Intravitreal Administration in Patients with Neovascular Age-related Macular Degeneration (Protocol Conquer / AM712E1001)

2022 - Principal Investigator - Opthea - A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age related Macular Degeneration (Protocol SHORE / OPT-302-1004)

David M. Brown MD FACS

Page 29

2022 - Principal & Sub-Investigator - 4D Molecular Therapeutics - Phase 1/2 Dose-Escalation and Dose-Randomized, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults with Neovascular Age-Related Macular Degeneration (Protocol Prism / 4d-150-C001)

2022 - Sub-Investigator - Aura Biosciences - A Prospective Matched Case-control Study of Visual Outcomes in Patients Treated with AU-011 or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/CM) (Protocol AU-011-402)

2022 - Sub-Investigator - Oyster Point - A Phase 2, Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (varenicline) Nasal Spray in Subjects with Neurotrophic Keratopathy (Protocol Olympia / OPP-102)

2022 - Sub-Investigator - Neurotech - Phase II, Multicenter, Open-label Safety Study of Bilateral NT-501 in Participants with Macular Telangiectasia Type 2 (Protocol NTMT-02B)

2022 - Principal Investigator - Zeiss - Evaluation of MODEL 6000 Angiography Image Quality and Comparison with MODEL 5000 (Protocol CIRRU-2021-2)

2022 - Sub-Investigator - Regenxbio - A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of Suprachoroidal Administration of RGX-314 for Diabetic Retinopathy Without Center Involved-Diabetic Macular Edema (Protocol Altitude LTF / RGX-314-5201)

2022 - Principal & Sub-Investigator - Roche - A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Diabetic Macular Edema (Protocol Alluvium / BP43445)

2022 - Sub-Investigator - Unity - A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration (Protocol Unity / UBX1325-02)

2022 - Principal & Sub-Investigator - Roche - A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study To Investigate The Efficacy, Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of RO7200220 In Combination With Ranibizumab Administered Intravitreally In Patients With Diabetic Macular Edema (Protocol Bardenas / BP43464)

2022 - Sub-Investigator - RCTX IST - Aqueous Biomarker Levels in DR and DME: The DRAGONS Prospective Study (Protocol DRAGONS)

2022 - Sub-Investigator - Genentech - A Phase IIb/IV, Multicenter, Open-Label, Single-Arm Study Of The Efficacy And Safety Of The Port Delivery System With Ranibizumab In Patients With Neovascular Age-Related Macular Degeneration Previously Treated With Intravitreal Agents Other Than Ranibizumab (Protocol Belvedere / ML43000)

2022 - Sub-Investigator - Oxurion - A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-687 injections and to evaluate the efficacy and safety of THR-687 versus aflibercept for the treatment of diabetic macular edema (Protocol Integral / THR-687-002)

2022 - Sub-Investigator - EyePoint Pharmaceuticals - A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide (FA) Intravitreal 0.05 mg Insert (Yutiq 0.05 mg) in Subjects with Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye (Protocol Calm / EYP-2102-001)

2021 - Sub-Investigator - Oyster Point Pharma - A Natural History Study of the Signs of Blepharitis with Bacterial Colonization of the Lid Margins (Protocol OPP-006)

2021 - Principal & Sub-Investigator - Boehringer Ingelheim - A First-in Human trial to study safety and tolerability of single rising intravitreal doses (open label, non-randomized, uncontrolled) and in addition the early biological response of multiple intravitreal doses (single-masked, randomized, sham controlled) of BI 765128 in panretinal photocoagulation treated proliferative diabetic retinopathy patients with diabetic macular ischemia (Protocol Partridge / 1451-0001)

David M. Brown MD FACS

Page 30

2021 - Principal & Sub-Investigator - Clearside Biomedical - Extension Study To Evaluate The Long-Term Outcomes Of Subjects Following CLS-AX Administration For Age-Related Macular Degeneration In The CLS-AX CLS1002-101 Study (Protocol Oasis Extension / CLS1002-102)

2021 - Principal & Sub-Investigator - Kodiak Sciences - A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (Protocol Glow / KS301P106)

2021 - Sub-Investigator - Ocular Therapeutix - A prospective, multi-center, randomized, parallel-group, phase 1 study to evaluate the safety, tolerability and efficacy of OTX-TKI (axitinib implant) for intravitreal use in subjects with previously treated neovascular age-related macular degeneration (Protocol OTX-TKI-2020-101)

2021 - Principal & Sub-Investigator - Sandoz Biopharmaceuticals - A 52-week Multicenter, Randomized, Double-Masked, 2-arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea, Administered Intravitreally, in Patients with Neovascular Age-related Macular Degeneration (Protocol MyLight / CSOK583A12301)

2021 - Principal & Sub-Investigator - Alexion Pharmaceuticals - A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (Protocol ALXN2040-GA-201)

2021 - Sub-Investigator - DRCR/Jaeb - A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening (Protocol AF)

2021- Principal & Sub-Investigator - Alkahest - A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral Akst4290 in Participants with Moderately Severe to Severe Diabetic Retinopathy (Protocol Capri / AKST 4290-231)

2021 - Sub-Investigator - Castle Biosciences - Molecular Predictive Testing in Ocular Melanoma - Pilot Study (Protocol CBI_2021_UN-MPTOM_00)

2021 - Sub-Investigator - Nanoscope Therapeutics - A Phase 2b/3 Randomized, Double-Masked, Sham-Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects with Advanced Retinitis Pigmentosa (Protocol RESTORE / NTXMCO-002)

2021 - Principal & Sub-Investigator - Ocuphire Pharma - Phase 2, Randomized, placebo-controlled, double-masked study of the safety and efficacy of orally administered APX3330 in subjects with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (Protocol ZETA-1 / OPI-APXDR-201)

2021 - Principal Investigator - Optos - Collection of modified P200DTx RGB Images (Protocol OPT1052)

2021 - Sub-Investigator - Opthea - A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age related Macular Degeneration (Protocol Coast / OPT-302-1005)

2021 - Principal & Sub-Investigator - Kodiak Sciences - A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (Protocol Daylight / KS301P107)

2021 - Principal & Sub-Investigator - Annexon - A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (Protocol Archer / ANX007-GA-01)

2021 - Principal & Sub-Investigator - Genentech - A Longitudinal, Biomarker Study of Anti-VEGF, to Explore the Relationship Between Aqueous Humor Composition and Multimodal Retinal Imaging in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema (Protocol Longitude / BP41783)

2021 - Sub-Investigator - RegenXBio- A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (Protocol Atmosphere / RGX-314-2104)

David M. Brown MD FACS

Page 31

2021 - Sub-Investigator - Novartis - A First-in-Human, Open-Label, Single Ascending Dose Study to Assess and Tolerability of Intravitreal MHU650 in Participants with Macular Edema from Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration, or Retinal Vein Occlusion (Protocol CMHU650A12101)

2021 - Principal & Sub-Investigator - Genentech - A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and tolerability of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (Protocol Avonelle-X / GR42691)

2021 - Principal & Sub-Investigator - Genentech - A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (Protocol Balaton / GR41984)

2021 - Principal & Sub-Investigator - Genentech - A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study To Evaluate The Efficacy And Safety Of Faricimab In Patients With Macular Edema Secondary To Central Retinal Vein Occlusion (Protocol Comino / GR41986)

2021 - Principal Investigator - Optos - Assessment of the modified P200TxE Silverstone (Protocol OPT1053)

2021 - Sub-Investigator - Regeneron - Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year Panorama Trial (Protocol Voyage).

2021 - Sub-Investigator - Regenxbio - A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two Doses in Two Formulations of RGX-314 Gene Therapy Administered via Subretinal Delivery in Participants with nAMD (Protocol RGX-314-2103)

2021 - Sub-Investigator - GlaxoSmithKline - Phase I, Open-label, Multi-Center Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 after 28 Day Repeat Oral Administration to Adults with Diabetic Macular Edema (Protocol GSK 212669)

2021 - Principal Investigator - MeiraGTx - Phase 3 Study of AAV2/5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene (Protocol Lumeos 021 / MGT-RPGR-021)

2021 - Sub-Investigator - Asceplix - Phase I/2a Study of the Safety and Bioactivity of AXT107 in Subjects with Neovascular Age-Related Macular Degeneration (Protocol SHASTA / AXT107-CS102)

2021 - Principal & Sub-Investigator - Apellis - A Phase 3, Open-Label, Multicenter, Extension Study To Evaluate The Long-Term Safety And Efficacy Of Pegcetacoplan In Subjects With Geographic Atrophy Secondary To Age-Related Macular Degeneration (Protocol Gale / APL2-305)

2021 - Principal & Sub-Investigator - Gyroscope Therapeutics - A Phase II, Open-Label, Outcomes-Assessor Masked, Multicentre, Randomised, Controlled Study To Evaluate The Safety And Efficacy Of Two Doses Of GT005 Administered As A Single Subretinal Injection In Subjects With Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration (Protocol Horizon / GT005-03)

2021 - Sub-Investigator - AsclepiX - Phase I/2a Study of the Safety and Bioactivity of AXT107 in Subjects with Diabetic Macular Edema (Protocol Congo / AXT107-CS101)

2021 - Principal & Sub-Investigator - Clearside Biomedical - Open-Label, Dose-Escalation, Phase 1/2A Study Of The Safety and Tolerability Of Suprachoroidally Administered CLS-AX Following Intravitreal Anti-VEGF Therapy In Subjects With Neovascular AMD (Protocol OASIS / CLS1002-101)

2021 - Sub-Investigator - Oxurion - A Phase 2, randomised, single-masked, active controlled, multicentre study to evaluate the efficacy and safety of THR-149 for the treatment of DME (Protocol Kalahari THR-149-002)

2021 - Principal & Sub-Investigator - Bayer - Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration (Protocol Pulsar 20968)

2020 - Sub-Investigator - Jaeb - Vitreous Proteomics in Eyes with a Macular Hole (Protocol AJ)

2020 - Sub-Investigator - Alimera Sciences - A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN Implant as Baseline Therapy in Patients with Early Diabetic Macular Edema (Protocol NEW DAY 01-20-005)

David M. Brown MD FACS

Page 32

2020 - Principal & Sub-Investigator - Genentech - An Exploratory, Prospective, Multi-Center, Open-Label, Single-Arm, Interventional, Phase IIb Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Patients with Diabetic Macular Edema and Diabetic Retinopathy Treated with Faricimab (Ro6867461) (Protocol Altimeter MR41926)

2020 - Principal & Sub-Investigator - Novartis - A 96-week, two-arm, randomized, single-masked, multicenter, phase III study assessing the efficacy and safety of brolocizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy (Protocol CONDOR CRTH258D2301)

2020 - Principal & Sub-Investigator - Adverum - A Long-term Study of ADV-022 in Neovascular (Wet) AMD - OPTIC Extension (Protocol OPTIC LTF ADV-022-07)

2020 - Principal Investigator - Optos - Assessment of Blue Autofluorescence in California Prototype (Protocol OPT1043)

2020 - Principal & Sub-Investigator - Novartis - A 64-Week, Two-Arm, Randomized, Double-Masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Brolocizumab 6 Mg Compared to Aflibercept 2 Mg in a Treat-To-Control Regimen in Patients with Neovascular Age-related Macular Degeneration (Protocol TALON Ext CRTH258A2303)

2020 - Principal & Sub-Investigator - Genentech - A Multicenter, Open-Label Extension Study To Evaluate The Long-Term Safety And Tolerability Of Faricimab In Patients With Diabetic Macular Edema (Protocol Rhone-X GR41987)

2020 - Principal & Sub-Investigator - Roche - A Phase 1 Open-Label, Two Part (Mad IVT and Port Delivery System) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7250284 in Patients with nAMD (Protocol Burgundy / BP41670)

2020 - Sub-Investigator - Jaeb/DRCR - Vitreous Proteomics in Eyes with a Macular Hole (Protocol AJ)

2020 - Principal & Sub-Investigator - SamChunDang Pharm - A Phase III Randomised, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity between SCD411 and Eylea® in Subjects with Neovascular Age-related Macular Degeneration (Protocol SCD411-CP101)

2020 - Sub-Investigator - Regenxbio Inc. - A Phase 2, Randomized, Dose-escalation, Observation-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via One or Two Suprachoroidal Space Injections in Participants with Diabetic Retinopathy Without Center Involved-Diabetic Macular Edema (Protocol Altitude RGX-314-2202)

2020 - Sub-Investigator - Regenxbio Inc. - A Phase 2, Randomized, Dose-escalation, Ranibizumab-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via One or Two Suprachoroidal Space (SCS) Injections in Participants with Neovascular Age-Related Macular Degeneration (Protocol AAVIATE RGX-314-2102)

2020 - Sub-Investigator - iRENIX Medical - Initial Human Factors, Safety, and Efficacy Trial of a Noval Pharmaceutical Intravitreal Injection Delivery System in Subjects Receiving Anti-VEGF (Protocol PRECISE CPRO-2003-001)

2020 - Sub-Investigator - Kodiak Sciences - A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (Protocol GLIMMER KS301P105)

2020 - Principal Investigator - Kodiak Sciences - A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (Protocol Gleam KS301P104)

2020 - Principal & Sub-Investigator - Kodiak Sciences - A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (Protocol Beacon KS301P103)

David M. Brown MD FACS

Page 33

2020 - Principal & Sub-Investigator - NGM Biopharmaceuticals Inc. - A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration (Protocol Catalina 621-GA-201)

2020 - Principal Investigator - Boehringer Ingelheim - Safety, tolerability and pharmacodynamics of single rising intravitreal and multiple rising intravitreal doses of BI 836880 in patients with wAMD (open label, non-randomized, uncontrolled) (Protocol 1336-0007)

2020 - Principal & Sub-Investigator - Roche - A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Retinopathy (Protocol Pavilion GR41675)

2020 - Sub-Investigator - Gemini Therapeutics, Inc. - A Multicenter, Open-label, Multiple Dose Study in Patients with Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103 (Protocol REGATTA GEM-CL-10302)

2020 - Principal & Sub-Investigator - Regeneron Pharmaceuticals - A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study Of The Efficacy And Safety Of High-Dose Aflibercept In Patients With Diabetic Macular Edema (Protocol Photon VGfTe-HD-DME-1934)

2020 - Principal Investigator - LumiThera - A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects with Dry Age-Related Macular Degeneration (Protocol LIGHTSITE III CSP005)

2020 - Principal Investigator - Amgen - A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration (Protocol 20170542)

2020 - Sub-Investigator - Adverum Biotechnologies, Inc. - A Phase 2, Multi-Center, Randomized, Double-Masked, Active Controlled Study of ADV-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema (Protocol Infinity ADV-022-04)

2020 - Principal & Sub-Investigator - Boehringer Ingelheim - A First-in Human trial to study safety and tolerability of single rising intravitreal doses (open label, non-randomized, uncontrolled) and in addition the early biological response of multiple rising intravitreal doses (single-masked, randomized, sham-controlled) of BI 764524 in panretinal photocoagulation (PRP) treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischemia (Protocol Hornbill 1436-0001)

2020 - Sub-Investigator - IVERIC Bio - A Phase 3 Multicenter, Randomized, Double-Masked, Sham Controlled Clinical Trial To Assess The Safety And Efficacy Of Intravitreal Administration Of Zimura™ (Complement C5 Inhibitor) In Patients With Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration (Protocol Gather2 ISEE2008)

2020 - Principal & Sub-Investigator - Gyroscope Therapeutics - A Study of Disease Progression in Genetically Defined Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Protocol GTSCOPE GYX01AMD)

2020 - Principal & Sub-Investigator - Roche - A Multi-Center, Randomized, Double-Masked, 40-Week, Parallel Group, Placebo-Controlled Proof Of Concept Study To Investigate The Efficacy And Safety Of Ro6868847 In Individuals With Diabetes Mellitus Type 1 Or Type 2 With Treatment Naïve Diabetic Retinopathy (Protocol Canberra BP41321)

2020 - Sub-Investigator - Regenxbio - Serum Anti-AAV8 Neutralizing Antibody Assessment Study of Patients with Neovascular Age-related Macular Degeneration or Diabetic Retinopathy (Protocol RGX-314-0101 / NAB)

2020 - Principal Investigator - Cleveland Clinic Foundation - Prospective Randomized Comparative Trial for Combination Dexamethasone Implant with PRN Anti-VEGF therapy to Anti-VEGF Therapy Alone in Treatment Resistant Diabetic Macular Edema: Informing the Role for Imaging Biomarkers and Combination Therapy (Protocol Precision)

2020 - Sub-Investigator - Aldeyra Therapeutics, Inc. - A multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy (Protocol The Guard ADX-2191)

David M. Brown MD FACS

Page 34

2019 - Principal & Sub-Investigator - Regeneron Pharmaceuticals - A randomized, single- masked, active- controlled phase 2 study of the safety, tolerability, and efficacy of repeated doses of high-dose aflibercept in patients with neovascular age-related macular degeneration (Protocol Candela VGFTe (HD)-AMD-1905)

2019 - Principal & Sub-Investigator - Genentech - Randomized, multicenter, open-label (visual assessor masked), active-comparator study evaluating the efficacy, safety, and pharmacokinetics of 100 mg/mL ranibizumab delivered via the PDS every 24 weeks or every 36 weeks compared with intravitreal ranibizumab 0.5 mg injections every 4 weeks in patients with diabetic retinopathy with or without diabetic macular edema (Protocol Pagoda GR40550)

2019 - Principal & Sub-Investigator - Graybug Vision, Inc. - A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneration (Protocol Altissimo GBV-102-002)

2019 - Principal & Sub-Investigator - Novartis - A Phase III, 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Study Assessing the Efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Visual Impairment due to Diabetic Macular Edema (Protocol Kingfisher CRTH258B2305)

2019 - Principal & Sub-Investigator - Kodiak Sciences - A Phase 2, Prospective, Randomized, Double-Masked, Controlled, Multicenter Study to Investigate Efficacy and Safety of Repeated Intravitreal Administration KSI-301 in Subjects with Wet AMD (Protocol Dazzle KSI-CL-102)

2019 - Principal Investigator - Boehringer Ingelheim - A Phase 1, Safety, tolerability and pharmacokinetics of single rising intravitreal doses of BI 754132 in patients with geographic atrophy secondary to age-related macular degeneration (open label, nonrandomized, uncontrolled) (Protocol BI 1418-0001)

2019 - Principal & Sub-Investigator - Novartis - A Phase III, Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multicenter Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (Protocol Raven CRTH258C2302)

2019 - Principal & Sub-Investigator - Novartis - A Phase III, Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multicenter Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion (Protocol Raptor CRTH258C2301)

2019 - Principal & Sub-Investigator - Outlook Therapeutics, Inc. - A Phase III, Clinical Effectiveness, Multicenter, Randomized, Double-Masked, Active Controlled Study Of The Efficacy And Safety Of Ons-5010 In Subjects With Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration (Protocol ONS-5010-002)

2019 - Principal Investigator - iRENIX - Clinical Evaluation of the P200TxE in Normal Eyes and Peripheral Pathology Eyes (Protocol INDY OPT-1039)

2019 - Principal & Sub-Investigator - Genentech - A Phase II, multicenter, randomized, single-masked, sham injection-controlled study of the safety, tolerability, and evidence of activity of intravitreal injection of RO7171009 in patients with Geographic Atrophy secondary (Protocol Gallego GR40973)

2019 - Sub-Investigator - Johns Hopkins / NEI / NIH - A Phase III multicenter randomized, parallel-treatment, comparative effectiveness trial comparing adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in the treatment of non-infectious, intermediate, posterior, and panuveitis (Protocol Advise 9196)

2019 - Sub-Investigator - NGM Biopharmaceuticals, Inc. - A Phase 1, Multicenter, Open-Label, Single-Dose and Multiple-Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravitreal Injections of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (Protocol 18-0501)

2019 - Principal & Sub-Investigator - Xbrane BioPharma - A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration (Protocol Xplore XBR1001)

2019 - Sub-Investigator - Stealth BioTherapeutics - A Phase II Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Elamipretide Solution in Subjects with Age-Related Macular Degeneration with Geographic Atrophy (Protocol ReCLAIM-2 SPIAM-202)

David M. Brown MD FACS

Page 35

2019 - Principal & Sub-Investigator - IONIS Pharmaceutical - A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (Protocol Golden / 696844-CS5)

2019 - Principal & Sub-Investigator - Roche - A Multi-Center, Non-Randomized, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of RO7200394 Following Intravitreal Administration in Patients with Neovascular Age-Related Macular (Protocol Bluetail BP40923)

2019- Sub-Investigator - Aura Biosciences – A registry of patients with primary choroidal melanoma or indeterminate lesions (Protocol AU-011-401)

2019 - Sub-Investigator - Recens Medical - Long term evaluation of the safety and efficacy of Cooling anesthesia for Local anesthesia during intravitreal injection (Protocol COOL-2)

2019 - Principal & Sub-Investigator - Senju Pharmaceuticals - A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the Treatment of Patients with Age Related Macular Degeneration (Protocol MT-0814 2-01)

2019 - Sub-Investigator - Aerie Pharmaceuticals - A Phase II, Multicenter, Open-label, Safety and Proof-of-concept Study to Assess Safety, Tolerability and Efficacy of AR-1105 in Subjects W. Macular Edema Due to Retinal Vein Occlusion (Protocol Orion AR-1105-CS201)

2019 - Principal & Sub-Investigator - Gemini Therapeutics - A Prospective Natural History Study to Evaluate Clinical Characteristics and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) Who Are Carriers of High-Risk Genetic Variants of Complement Factor H (Protocol Clarity 002 GEM-NH-002)

2019 - Principal & Sub-Investigator - Gemini Therapeutics - A Genetic Screening and Registry Study to Evaluate Long-term Clinical Outcomes and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) Who Are Carriers of High-Risk Genetic Complement Variants Associated with Dry Age-related Macular Degeneration (Protocol Clarity 001 GEM-NH-001)

2019 - Sub-Investigator - Roche - A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator–Controlled Study To Evaluate The Efficacy And Safety Of Faricimab In Patients With Neovascular AMD (Protocol Lucerne GR40844)

2019 - Principal Investigator - Roche - A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator–Controlled Study To Evaluate The Efficacy And Safety Of Faricimab In Patients With Neovascular AMD (Protocol Tenaya GR40306)

2019 - Principal & Sub-Investigator - Kodiak Sciences - A Phase I/Ib Open Label, Multi-Center Exploratory Study To Investigate The Bioactivity, Ocular And Systemic Safety, Tolerability, And Pharmacokinetics Following Single And Multiple Intravitreal Administrations Of KSI-301 In Subjects With Wet AMD, DME And RVO (Protocol KSI-CL-101)

2019 - Sub-Investigator - Recens Medical - A Phase I dose ranging study evaluating the safety and efficacy of Cooling anesthesia for Local anesthesia during intravitreal injection (Protocol COOL 1)

2019 - Principal & Sub-Investigator - Chengdu Kanghong Pharmaceuticals - A Phase III, Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration (Protocol Panda2 KHB-1802)

2019 - Sub-Investigator - Chengdu Kanghong Pharmaceuticals - A Phase III, Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration (Protocol Panda1 KHB-1801)

2019 - Principal Investigator - BIRC - Longitudinal Observational Study of Non-Exudative Age-Related Macular Degeneration Imaged with Swept Source Optical Coherence Tomography (Protocol Impact Swagger BIRC-01)

2018 - Sub-Investigator - Apellis - A 24-Month Phase Ib Multi-Center, Open Label Study to Evaluate the Safety of Intravitreal APL-2 Therapy in Patients Diagnosed with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (Protocol APL2-103 - SAFETY STUDY)

David M. Brown MD FACS

Page 36

2018 - Principal & Sub-Investigator - Regeneron - A Phase IV Study In Patients With Chorioretinal Vascular Disease To Evaluate An Aflibercept (Eylea®) Prefilled Syringe (Protocol VGFTe-OD-1881)

2018 - Sub-Investigator - Neurotech Pharmaceuticals - A Phase III Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2 (Protocol MacTel NTMT-03-B)

2018 - Principal & Sub-Investigator - Mylan - A Phase III, Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects with Diabetic Macular Edema (Protocol MYL-1701P-3001)

2018 - Sub-Investigator - Santen - A Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye (Protocol Lumina 010906IN)

2018 - Principal & Sub-Investigator - Roche - A Phase III, Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects with Diabetic Macular Edema (Protocol Archway GR40548)

2018 - Principal Investigator - Roche - A Multicenter, Open-Label Extension Study To Evaluate The Long-Term Safety And Tolerability Of The Port Delivery System With Ranibizumab In Patients With Neovascular Age-Related Macular Degeneration (Protocol Portal GR40549)

2018 - Principal & Sub-Investigator - Novartis - A multicenter, randomized, double-masked Phase IIIa study to assess safety and efficacy of brolucizumab 6 mg q4 weeks compared to aflibercept 2 mg q4 weeks in patients with neovascular age-related macular degeneration with persistent retinal fluid (Protocol Merlin CRTH258AUS04)

2018 - Sub-Investigator - The Lowy Medical Research Institute - A Natural History Observation and Registry Study of Macular Telangiectasia Type 2 The MacTel Study (Protocol MacTel NHOR)

2018 - Principal & Sub-Investigator - Adverum Biotechnologies - A Dose-Ranging Study Of Intravitreal OPT-302 In Combination With Ranibizumab, Compared With Ranibizumab Alone, In Participants With Neovascular Age-Related Macular Degeneration (Protocol Optic ADVM-022-1)

2018 - Principal Investigator - Roche - A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator Controlled Study To Evaluate The Efficacy And Safety Of RO6867461 In Patients With [both previously treated and treatment naïve] DME (Protocol Rhine GR40398 [TMC])

2018 - Sub-Investigator - Roche - A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator Controlled Study To Evaluate The Efficacy And Safety Of RO6867461 In Patients With [both previously treated and treatment naïve] DME (Protocol Yosemite GR40349 [WL])

2018 - Sub-Investigator - Apellis - A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Protocol Derby APL2-303 [WL])

2018 - Principal Investigator - Apellis - A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Protocol Oaks APL2-304 [TMC])

2018 - Principal Investigator - Santen - A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Wet Age-related Macular Degeneration (Protocol Avante 36-002)

2018 - Principal & Sub-Investigator - Novartis - Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (Protocol Kestrel CRTH258B2301)

2018 - Principal Investigator - Thrombogenics - A Phase I, Open-Label, Multicenter, Dose Escalation Study To Evaluate The Safety Of A Single Intravitreal Injection Of THR-149 For The Treatment Of Diabetic Macular Edema (Protocol THR-149-001)

David M. Brown MD FACS

Page 37

2018 - Sub-Investigator - Clearside Biomedical - A Phase III, Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Anti-VEGF Agent in Subjects With Retinal Vein Occlusion (Protocol Topaz CLS1003-302)

2018 - Principal & Sub-Investigator - Allergan - A Phase II Study Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration (Protocol Maple 1771-201-008)

2018 - Principal & Sub-Investigator - Adverum Biotechnologies - Blood Specimen Collection Study for the Measurement of Adeno-Associated Virus (AAV) Neutralizing Antibodies in Subjects with Neovascular (Wet) Age-Related Macular (Protocol NAB ADVM-022-2)

2018 - Principal & Sub-Investigator - Opthea Limited - Phase Ib/Ila study of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema (Protocol OPT-302-1003)

2018 - Principal & Sub-Investigator - Greater Houston Retina Research/Regeneron - Assess the safety of 2 mg intravitreal aflibercept injections (IAI) to achieve and maintain DRSS improvements (2 or more steps) in patients with a baseline DRSS level of 47A to 71A inclusive through 52 weeks as determined by reading center determined DRSS gradings on OPTOS fundus photos and leakage index on OPTOS WF-FA (Protocol Prime VGFTe-DR-1822)

2018 - Principal & Sub-Investigator - Samsung Bioepis - Phase III Randomized, Double-masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB11 (proposed ranibizumab biosimilar) and Lucentis® in Subjects with Neovascular Age-Related Macular Degeneration (Protocol SB11-G31-AMD)

2018 - Sub-Investigator - DRCR Network - PROMINENT-Eye Ancillary Study (Protocol AD)

2018 - Principal Investigator - Apellis Pharmaceuticals - A Randomized Controlled Trial Comparing The Effect Of Topical Dorzolamide-timolol Versus Placebo Combined With Intravitreal Anti-vascular Endothelial Growth Factor Injections In Patients With Neovascular Age-related Macular Degeneration Who Are Incomplete Anti-VEGF Responders (Protocol Furlong APL2-203)

2018 - Sub-Investigator - DRCR Network - Randomized Trial of IVT Aflibercept Versus IVT Bevacizumab + Deferred Aflibercept for Treatment of CI-DME (Protocol AC)

2018 - Novartis Pharmaceuticals- A Phase III 24-week, double-masked, multicenter, two-arm extension study to collect safety and efficacy data on brolucizumab 6 mg drug product intended for commercialization in patients with neovascular age-related macular degeneration who have completed the CRTH258A2301 study (Protocol HAWK EXTENSION/ CRTH258A2301E)

2018 - Principal & Sub-Investigator - Opthea Limited - A Phase I Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Wet AMD (Protocol OPT-302-1002)

2017 - Sub-Investigator - Boehringer Ingelheim - Assess the safety of 2 mg intravitreal aflibercept injections (IAI) to achieve and maintain DRSS improvements (2 or more steps) in patients with a baseline DRSS level of 47A to 71A inclusive through 52 weeks as determined by reading center determined DRSS gradings on OPTOS fundus photos and leakage index on OPTOS WF-FA (Protocol Robin 1382.12)

2017 – Sub-Investigator – Wills Eye - A Randomized Controlled Trial Comparing the Effect of Topical Dorzolamide-Timolol versus Placebo Combined with Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Patients with Neovascular Age-Related Macular Degeneration Who Are Incomplete Anti-VEGF Responders (Protocol Dawn [RCT Cosopt] 16-596)

2017 - Principal Investigator - Heidelberg Engineering - Evaluation of the Heidelberg Engineering SPECTRALIS with OCT Angiography Module (Protocol Heidelberg S-2017-1)

2017 – Sub-Investigator – Clearside Biomedical, Inc. – A Phase II Randomized, Double Masked, Controlled Study Comparing the Safety and Efficacy of Suprachoroidal CLS-TA with Intravitreal Aflibercept versus Aflibercept Alone in Subjects with Diabetic Macular Edema (Protocol Tybee CLS1004-201)

2017 - Principal & Sub-Investigator - Aerpio Therapeutics - Phase II Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy (Protocol Time2B AKB-9778-CI-5001)

David M. Brown MD FACS

Page 38

2017 – Principal Investigator – Pennsylvania State University – Long Term Follow Up of Score2 Study (Score2 LTF)

2017 - Principal & Sub-Investigator - Taiwan Liposome Company - A Phase IIa Trial of TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability (Protocol TLC399A2002)

2017 - Sub-Investigator – Clearside Biomedical, Inc. - Phase III Open-label safety study of suprachoroidal Triamcinolone Acetonide injectable suspension in patients with non-infectious uveitis (Protocol Azalea / CLS1001-302)

2017 - Sub-Investigator - Regeneron - The ARRT trial will assess the safety and efficacy of 2mg IAI for the treatment of radiation retinopathy, including maculopathy and optic neuropathy (Protocol ARRT)

2017 - Sub-Investigator - Aldeyra Therapeutics, Inc. - A Phase III, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis (Protocol Solace ADX-102-UV-005)

2017 - Sub-Investigator – AURA Biosciences - Phase Ib Open-Label, single ascending dose clinical trial designed to evaluate the safety of two dose levels of light-activated AU-011-101 for the treatment of subject with small to medium (2.0mm-3.4mm thickness) primary choroidal melanoma (Protocol Aura / AU-011-101)

2017 - Sub-Investigator - Clearside Biomedical, Inc. - A Phase III, Randomized, Masked Controlled Trial to Study the Safety And Efficacy of Suprachoroidal CLS-TA In Conjunction with IntraVitreous Aflibercept in Subjects with Retinal Vein Occlusion (Protocol Sapphire / CLS1003-301)

2017 – Sub-Investigator – Quan Dong Nguyen – An Open-label, Multi-center, Randomized, Phase II Study of the Safety, and Bioactivity of Two Dose Regimens of Subcutaneous Injections of ACTH Gel in Patients with Non-infectious Uveitis (Protocol ACTHAR-01)

2016 - Sub-Investigator- Allergan - Evaluation of Safety and Systemic Pharmacokinetics After Single and Repeat Doses of Abicipar Pegol (AGN-150998) Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration (Protocol Sapling / 150998-012)

2016 - Sub-Investigator - Clearside Biomedical, Inc. - A Phase III, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis (Protocol Magnolia / CLS1001-303)

2016 - Sub-Investigator - NEI - Macular Edema Ranibizumab Vs. Intravitreal Anti-Inflammatory Therapy (Protocol Merit 119247)

2016 - Sub-Investigator - Quark Pharmaceuticals - A Phase II/III, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (Protocol QRK207)

2016 - Sub-Investigator – Clearside Biomedical, Inc. - Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (Protocol HULK CLS1004-101)

2016 - Principal Investigator – SciFluor LIFE SCIENCES INC. - A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Diabetic Macular Edema (Protocol SciFluor SF0166-C-001)

2016 - Sub-Investigator - Investigator Sponsored - Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy (Protocol Recovery)

2016 - Principal & Sub-Investigator – Roche - A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study (Protocol Omaspect GX30191)

David M. Brown MD FACS

Page 39

2016 – Principal & Sub-Investigator - OHR Pharmaceuticals - A Phase II Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (Protocol Mako OHR-1601)

2016 - Sub-Investigator – Novartis - A Randomized, Active-controlled, Open-label, Multicenter proof-of Concept Study of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, Posterior-, or Panuveitis Requiring Systemic Immunosuppressive Therapy (Protocol CLFG316-A2204)

2016 - Principal & Sub-Investigator – Regeneron - A Randomized, Double-Masked, Active-Controlled Phase II Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration (Protocol Onyx R910-3-AMD-1517)

2016 - Sub-Investigator – Ophthotech- A Phase II/III Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura® (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (Protocol OPH2003)

2016 - Sub-Investigator – NEI/NIH sponsored DRCR.net – Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk (Protocol W)

2016 - Principal & Sub-Investigator - Regeneron - A Randomized, Double-Masked, Active-Controlled, Phase II Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema (Protocol Ruby R910-3-DME-1518)

2016 - Principal Investigator - Regeneron - Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection versus Sham as Prophylaxis against Conversion to Neovascular Age-Related Macular Degeneration in High-Risk Eyes (Protocol Pro-Con VGFTe-AMD-1507)

2016 - Principal & Sub-Investigator - Regeneron - Study of the Efficacy and Safety of Intravitreal Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (Protocol Panorama VGFTe-OD-1411)

2016 - Principal & Sub-Investigator - Roche - A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 28- week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with diabetic macular edema (Protocol Boulevard BP30099)

2016 - Principal & Sub-Investigator- Clearside Biomedical, Inc. - A Phase III, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis (Protocol Peachtree / CLS1001-301)

2016 - Principal Investigator – Genentech - Phase II Multicenter, Randomized, Active Treatment-Controlled Study of The Efficacy and Safety of The Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration. (Protocol Ladder GX28228)

2015 - Principal Investigator - Allegro Ophthalmics, LLC - A Phase II, Randomized, Double-masked, Placebo-controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy of Luminate in Inducing PVD in Subjects with Non-Proliferative Diabetic Retinopathy (Protocol Allegro PVD-202)

2015 - Principal & Sub-Investigator - Allergan - A safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration (Protocol Cedar 150998-005-CEDAR)

2015 - Principal & Sub-Investigator - Roche - A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RG7716 Administered Intravitreally in Patients With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Protocol Avenue BP29647)

2015 - Principal Investigator - Clearside Biomedical - A Phase II, Multicenter, Randomized, Active Controlled Study Of The Safety And Efficacy Of A Suprachoroidal Administration Of CLS1001, Triamcinolone Acetonide Injectable Suspension Plus An Intravitreal Injection Of Eylea In Subjects With Macular Edema Following Retinal Vein Occlusion (Protocol Clearside RVO CLS1003-201)

David M. Brown MD FACS

Page 40

2015 - Principal & Sub-Investigator - Apellis - A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients Geographic Atrophy (Protocol Filly POT-CP121614)

2015 - Principal Investigator - Tyrogenex - A Randomized, Double-Masked, Placebo-Controlled, Dose- Finding, Non-Inferiority Study of X-82 Plus Prn Intravitreal Anti-VEGF Compared to Prn Ivt Anti-VEGF Monotherapy in Neovascular AMD (Protocol X82-OPH-201)

2015 - Principal & Sub-Investigator - Regeneron - A Phase II, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration (Protocol Capella R2176-3-AMD-1417)

2015 - Principal Investigator - Iconic Therapeutics - A Phase II Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hi-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (Protocol Emerge IT-002)

2015 - Principal Investigator - Roche - An Epidemiologic Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Protocol Proxima B GX29639)

2015 - Principal Investigator - Ophthotech Corporation - An 18-Month Phase IIa Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer) (Protocol OPH1006)

2015 - Sub-Investigator - NEI - Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (Protocol Point IRB00006139)

2015 - Principal Investigator - Astellas - A Phase II, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (Protocol VIDI 8232-CL-3001)

2014 - Principal Investigator - Alcon - A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration (Protocol Hawk RTH258-C001)

2014 - Principal Investigator - NEI/NIH sponsored DRCR.net - Peripheral DR Lesions on Ultrawide-field Fundus Images and Risk of Diabetic Retinopathy Worsening Over Time (Protocol AA)

2014 - Principal Investigator - The EMMES Corporation - Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks (Protocol SCORE2)

2014 - Principal Investigator - Thrombogenics - This is a multicenter, prospective, observational, Phase IV study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (Protocol Orbit TG-MV-018)

2014 - Principal Investigator - Alcon - A Multicenter, Single-Masked, Sham-Controlled, Randomized, Parallel-Group Study To Assess The Safety And Efficacy Of Perflutren Lipid Microsphere-Assisted ultrasound Thrombolysis In Subjects With Branch Retinal Vein Occlusion (Protocol Reflow C-13-036)

2014 - Principal Investigator - Genentech - A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study To Assess The Efficacy And Safety Of Lampalizumab Administered Intravitreally To Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration (Protocol Spectri GX29185)

2014 - Principal Investigator - Allegro Ophthalmics - A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate® (ALG-1001) as Compared to Avastin® in the Treatment of Diabetic Macular Edema (Protocol Allegro DME 202B)

2014 - Sub-Investigator - Investigator Sponsored Trial - Retrospective Analysis of Retinal Diseases

David M. Brown MD FACS

Page 41

2014 - Principal Investigator - Pfizer - A Phase II, Randomized, Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist (PF-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema (Protocol Pfizer DME B1261009)

2014 - Sub-Investigator - Allegro Ophthalmics - A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion (Protocol Allegro VMT)

2014 - Sub-Investigator - Investigator Sponsored Trial; Regeneron - Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema in Patients Who Completed the Three-Year VISTA-DME Trial (Protocol The Endurance 1 Trial)

2014 - Principal Investigator - Aerpio Therapeutics - A Phase II, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema (Protocol TIME-2 AKB-9778-CI-2003)

2014 - Sub-Investigator - NEI/NIH sponsored DRCR.net - Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involvement Diabetic Macular Edema Following Anti-VEGF Therapy in Pseudophakic Eyes (Protocol U)

2013 - Sub-Investigator - Palmetto Retina Center - Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-Related Macular Degeneration Extension Study Protocol VGFT-OD 0910 (Protocol Range VGFT-OD-1319)

2013 - Sub-Investigator - pSivida Corp - A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye (Protocol PSV-FAI-001)

2013 - Sub-Investigator - NEI/NIH sponsored DRCR.net - Treatment for Central-Involvement Diabetic Macular Edema in Eyes with Very Good Visual Acuity (Protocol V)

2013 - Principal Investigator - QLT Inc. - An Open-Label, Phase Ib, Safety/Proof-of-Concept Study to Evaluate the Effects of Oral QLT091001 in Retinitis Pigmentosa (RP) Subject with an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)

2013 - Sub-Investigator - Ophthotech - A Phase III Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Fovista (E10030) Intravitreal Administration in Combination With Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration (Protocol OPH1003)

2013 - Principal Investigator - Genzyme - A Phase I, Open-Label, Multi-Center, Dose-Escalating Safety and Tolerability Study of a Single Intravitreal Injection of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (Protocol sFLT01-AMD-00106)

2013 - Principal Investigator - Ampio - A Phase III Randomized, Placebo-controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina in Adult Patients with Diabetic Macular Edema (Protocol AP-05-002)

2013 - Principal Investigator - Alcon - A Phase II Prospective, Randomized, Double-Masked, Multi-Center, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 versus EYLEA in Subjects with Exudative Age-Related Macular Degeneration (Protocol C-12-006)

2013 - Principal Investigator - Acucela - A Phase IIb/III Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated with Dry Age-Related Macular Degeneration (Protocol SEATTLE ACU-4429-202)

2012 - Sub-Investigator - XOMA (US) LLC Eye Guard 'C' Trial - A Phase III Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-Infectious Intermediate, Posterior, or Pan-Uveitis Currently controlled With Systemic Treatment (Protocol Eye-Guard C X052131 CL3-78989-006)

David M. Brown MD FACS

Page 42

2012 - Sub-Investigator - XOMA (US) LLC Eye Guard 'A' Trial- A Phase III Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Infectious Intermediate, Posterior, or Pan-Uveitis (Protocol Eye-Guard A X052130 / CL3-78989-005)

2012 - Sub-Investigator - A Phase IIIb, Multicenter, Randomized, Controlled Study of the Safety, Tolerability and Efficacy of Intravitreal Injections of 0.5mg Ranibizumab Given Monthly Compared to a Treat and Extend Protocol in Patients with Wet-Age-Related Macular Degeneration (Protocol TREX AMD ML28513)

2012 - Sub-Investigator - Greater Houston Retina Research / Genentech - A Phase I/II, Open Label, Multicenter, Randomized, Controlled Study of the Safety, Tolerability and Efficacy of Intravitreal Injections of 0.3mg Ranibizumab Given Monthly Compared to a Treat and Extend Protocol in Patients with Diabetic Macular Edema (Protocol TREX DME ML28724) IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months (Protocol Wave 12246)

2012 - Principal Investigator - Xcovery Vision / Tyrogenex- A Phase I/II Open-Label, Dose Escalation Clinical Trial To Evaluate The Safety And Preliminary Biologic Activity/Efficacy Of The VEGFR/ PDGFR Inhibitor X-82 Administered Per OS In Subject With Neovascular Age-Related Macular Degeneration (Protocol X82-OPH-102)

2012 - Principal Investigator - Regeneron - A Phase IV Open-Label Study Of The Efficacy, Safety, And Tolerability Of Intravitreal Administration Of VEGT Trap-Eye (Intravitreal Injection) In Patients With Neovascular Age-Related Macular Degeneration (Protocol Re-view VGFTe-AMD-1124)

2012 - Principal Investigator - Johns Hopkins University - A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema With Involvement of the FoveAL Center (Protocol iDEAL 2010-007-03-DME)

2012 - Sub-Investigator - NEI/NIH sponsored DRCR.net - A Comparative Effectiveness Study Of Intravitreal Aflibercept, Bevacizumab and Ranibizumab For Diabetic Macular Edema (Protocol T)

2012 - Sub-Investigator - NEI/NIH sponsored DRCR.net - Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab With Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (Protocol S)

2012 - Principal Investigator - Quark Pharmaceuticals - A Phase II Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With a Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating the Efficacy and Safety of PF-04523655 Alone and in Combination With Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema (Protocol MATISSE QRK202)

2012 - Principal Investigator - Regeneron - A Phase III, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of VEGF Trap-Eye compared to laser treatment in patients with macular edema secondary to BRVO (Protocol VIBRANT VGFTe-RVO-1027)

2012 - Sub-Investigator – IDx LLC - A Multicenter Masked Study to compare analysis of the detection program IDx-DR against Standard of Care Clinical Examination by Ophthalmologists to Differentiate Levels of Diabetic Retinopathy and Diabetic Macular Edema (Protocol 001)

2012 - Principal Investigator - Investigator Sponsored Trial: Genentech - A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.5mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months, Then PRN vs. 0.5mg Ranibizumab 4 Months Monotherapy, Then as Needed (Protocol DAVE Trial ML27954)

2012 - Sub-Investigator – Investigator Sponsored Trial: Greater Houston Retina Research - A Phase III Randomized 1:1, Masked, Study of the Safety, Tolerability, and Efficacy of Intravitreal Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Adjuvant Management of TRD and Vit Hem Associated With PDR (Protocol Macugen No-Crunch 01)

David M. Brown MD FACS

Page 43

2012 - Principal Investigator - Investigator Sponsored Trial: Greater Houston Retina Research / Regeneron - Study of Aflibercept for Subjects Who Are Incomplete Responders to multiple Intravitreal Injections of Ranibizumab, Anti-VegF (Protocol TURF-01)

2012 - Sub-Investigator - Notal Vision - Foresee Home for Monitoring Age Related Macular Degeneration (Protocol Foresee HOME-02)

2012 - Principal Investigator - Optos/NEI - Optos PERipheral retina AREDS II Ancillary Study (Protocol OPERA)

2012 - Principal Investigator – LPATH, INC. - A Phase IIa, Comparator Controlled Study Evaluating iSONEP™ as Monotherapy or Adjunctive Therapy to Lucentis®/Avastin® Versus Lucentis®/Avastin® Alone for the Treatment of Subjects With CNV Secondary to AMD (Protocol LT1009-Oph-003)

2011 - Principal Investigator - GSK Phase IIa Open Label pazopanib eyedrop study for neovascular age-related macular degeneration (Protocol MD-7114987)

2011 - Sub-Investigator - Santen - Phase III Intravitreal Injections of DE-109 (3 doses) for the treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye (Protocol Sakura 32-007)

2011 - Principal Investigator - Allergan - Single Dose Study of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-related Macular Degeneration (Protocol Reach 150998-001)

2011 - Principal Investigator - Alimera - A Phase III Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study (Protocol C-01-11-008)

2011 - Principal Investigator - GSK - A Phase II, Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients With GA Secondary to AMD (Protocol BAM OVG-2013/04)

2011 - National Steering Committee & Principal Investigator- Regeneron - A Double-Masked, Randomized, Active-Controlled, Phase III Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema (Protocol VISTA DME VGFT-OD-1009)

2011 - Sub-Investigator - ThromboGenics - Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriclasmin Studies. (Protocol TG-MV-012)

2011 - Sub-Investigator - ThromboGenics- A Phase II Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriclasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (Protocol Oasis TG-MV-014)

2011 - Sub-Investigator - ThromboGenics- A Phase II Randomized, Sham-Injection Controlled, Double-Masked, Multicenter Trial of Ocriclasmin Intravitreal Injection for Treatment of Focal Vitreomacular Adhesion in Subjects With Exudative Age-Related Macular Degeneration (Protocol MIVI-5 TG-MV-005)

2011 - Principal Investigator - Allergan - Phase I/II Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (Protocol 208397-001)

2010 - Principal Investigator – Greater Houston Retina Research/Genentech - A Phase I Open Label Study of the Safety, Tolerability and Efficacy of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (Protocol RAVE2 FVF4820s)

2010 - Sub-Investigator - AbbVie/Abbott - A Phase III Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients (Protocol Visual II M10-880)

2010 - Sub-Investigator - AbbVie/Abbott- A Phase IIIMulticenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients (Protocol Visual I M10-877)

David M. Brown MD FACS

Page 44

2010 - Sub-Investigator - AbbVie - A Phase III Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (Protocol Visual III M11-327)

2010 - Sub-Investigator - Ophthotech - A Phase I Study, Ascending Dose And Parallel Group Trial To Establish The Safety, Tolerability And Pharmacokinetic Profile Of Multiple Intravitreal Injections Of Volociximab (A5 β 1 Integrin Antagonist) As Monotherapy Or In Combination With Lucentis 0.5 Mg/Eye In Subjects With Neovascular AMD (Protocol OPH3000)

2010 - Sub-Investigator - Ophthotech - A Phase II, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration (Protocol OPH1001)

2010 - Sub-Investigator - Allergan – A Phase II Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System (Protocol 190342-033D)

2010 - Principal Investigator - Molecular Partners - A Phase I/II, Open-label, Single Ascending Dose Study Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of Intravitreal MP0112 in Patients With Diabetic Macular Edema (Protocol MP0112-CP02)

2010 - Sub-Investigator – Peter A. Campochiaro/Genentech - Extended Follow-up of Patients With Macular Edema Due to Branch Retinal Vein Occlusion or Central Retinal Vein Occlusion (CRVO) Previously Treated With Intravitreal Ranibizumab originally enrolled in the BRAVO & CRUISE trials and subsequently followed in the HORIZON extension trial (Protocol Retain NA_00040287)

2010 - Principal Investigator - Genentech - Phase IV Ranibizumab dosing frequency trial (Protocol SHORE RVO)

2009 - Sub-Investigator - Novartis - GA Observational Registry/Cohort (Protocol PJMR0092103)

2009 - Principal Investigator - David M. Brown/Genentech - A Phase I/II Open Label, Multiple Intravitreal Injections of (Super-dose Anti-VEGF) 2.0mg Ranibizumab in Subjects With Chronic Fluid on OCT Post Multiple Injections With Ranibizumab (Protocol SAVE FVF4571s)

2009 - Sub-Investigator - Alcon – Phase III Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (Protocol GATE C-08-36)

2009 - Principal Investigator & National Steering Committee - Genentech - A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Subfoveal Neovascular Age-related Macular Degeneration (Protocol HARBOR FVF4579g & GX01511)

2009 - Principal Investigator - Allergan- Posurdex for Neovascular AMD in combination with Ranibizumab Phase III trial

2009 - Principal Investigator - Schering Plough PO5185 High Resolution Ocular Imaging of Patients with Atherosclerotic Disease

2009 - Principal Investigator - Regeneron - A Randomized, Double Masked, Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (Protocol VGFT-OD-0819)

2009 - Sub-Investigator - Regeneron - A Phase III Open-label, Long-term, Safety and Tolerability Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Protocol VGFT-OD-0910)

2009- Sub-Investigator - Regeneron - A Phase II Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema (Protocol DA VINCI VGFT-OD-0706)

2008- National Steering Committee- Genentech - A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (Protocol RISE FVF4170g)

David M. Brown MD FACS

Page 45

2008- National Steering Committee- Genentech - A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (Protocol RIDE FVF4168g)

2008- International Steering Committee - A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (Protocol VIEW2 91689)

2008- National Steering Committee - A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration (Protocol VIEW1 VGFT-OD-0605)

2008- Sub-Investigator - ThromboGenics - A Phase III Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion (Protocol TG-MV-006)

2008 - Sub-Investigator - Novartis - An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis (Protocol CAIN457A2208)

2008 - Sub-Investigator - Allergan – Phase II Safety and Efficacy Trial of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to AMD (Protocol 190342-032D)

2008 - Principal Investigator - Alimera - A Phase III Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 µg/Day and ASI-001B 0.2 µg/Day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects With Diabetic Macular Edema (Protocol FAME C-01-05-001)

2007 - Principal Investigator - NEI/University of Pennsylvania Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (Protocol CATT)

2007 - Principal Investigator - TargeGen - Phase IIa Open-Label Randomized Pilot Study of Safety and Preliminary Efficacy of TG100801 in Patients With Choroidal Neovascularization Due to Age-Related Macular Degeneration (Protocol OPH-TG100801-002)

2007 - Principal Investigator - Neurotech - A Phase II Study of Implants of Encapsulated Human NTC-201 Cells Releasing Ciliary Neurotrophic Factor (CNTF), in Participants With Visual Acuity Impairment Associated With Atrophic Macular Degeneration (Protocol CNTF 2)

2007 - Principal Investigator - Othera - A Phase II Study of OT-551 Antioxidant Eye Drop in Participants With Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration (Protocol 060116)

2007 - Principal Investigator - Genentech - A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion (Protocol BRAVO FVF4165g)

2007 - Principal Investigator - Genentech - A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (Protocol CRUISE FVF4166g)

2007- Principal Investigator - Genentech - A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (Protocol RISE FVF4170g)

2007- Principal Investigator - Genentech - A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (Protocol RIDE FVF4168g)

2006 - Principal Investigator - Alcon AL-39324 - Phase I Intravitreal Tyrosine Kinase Inhibitor in treatment of wet ARMD

2006 - Sub-Investigator - ThromboGenics - A Multicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy (Protocol MIVI III TG-MV-003)

David M. Brown MD FACS

Page 46

2006 - Sub-Investigator - Regeneron - Intravitreal VEGF-Trap in the treatment of wet ARMD

2006 - Principal Investigator - Pfizer - Phase I trial of intravitreal Tyrosine Kinase inhibitor (VEGF-2 receptor blocking molecule) in the treatment of wet ARMD (Protocol AG-013958)

2006 - Principal Investigator- Phase I Study of .03 mg and .05 mg Ranibizumab in Subjects With Ischemic CRVO (Protocol RAVE)

2006 - Principal Investigator - National Eye Institute - Age-Related Eye Disease Study 2: A Multi-center, Randomized Trial of Lutein, Zeaxanthin and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration (Protocol AREDS2 NEI-120)

2005 - Principal Investigator - Eli Lilly- Phase III The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema

2005 - Principal Investigator - Genentech - A Phase IIIB, Single-Masked, 1-Year Multicenter Study Of The Safety And Tolerability Of Intravitreally Administered Ranibizumab In Subjects With Active Subfoveal CNV Secondary To AMD (Protocol Sailor FVF3689g)

2005 - Sub-Investigator - Novartis Pharmaceuticals - A 24-month Randomized, Double-masked, Sham Controlled, Multicenter, Phase IIIB Study Comparing Photodynamic Therapy With Verteporfin (Visudyne®) Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide (1 mg and 4 mg) Versus Visudyne® Plus Intravitreal Pegaptanib(Macugen®) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (Protocol VERITAS CBPD952E2202)

2005 - Principal Investigator - OPKO Health - A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration (Protocol ACU201)

2005 - Sub-Investigator - NEI - A Phase IV Multicenter Uveitis Steroid Treatment trial investigating fluocinolone acetonide sustained release device in refractory uveitis (Protocol MUST)

2005 - Principal Investigator - Allergan - Posurdex Dexamethasone Device Phase III trial for diabetic macular edema.

2005 - Principal Investigator - Mateon Therapeutics - A Phase II, Dose Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of Combretastatin A4 Phosphate for Treating Subfoveal Choroidal Neovascularization in Subjects With Pathologic Myopia (Protocol MMD-213)

2005 - Principal Investigator - Eyetech - Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD) (Protocol EOP1012)

2004 - Principal Investigator - Genentech - A Phase IIIB, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects With Subfoveal Choroidal Neovascularization (CNV) With or Without Classic CNV Secondary to Age Related Macular Degeneration (Protocol PIER FVF3192g)

2004 - Principal Investigator - Allergan - A Phase III Study of the Safety and Efficacy Of An Intravitreal Implant Of Dexamethasone For Macular Edema Resulting From Retinal Vein Occlusion (Protocol 206207-009)

2004 - Sub-Investigator - Novartis /QLT/ Manhattan Eye, Ear & Throat Hospital: Richard Spaide, MD - A Randomized, Single-Masked, Multi-Center, Phase 2 Evaluation Of The Effect Of PDT Using Visudyne In Combination With Intravitreal Injection Of Either 0 mg, 1mg or 4mg of Kenalog In Subfoveal Occult & Minimally Classic CNV Secondary To ARMD (Protocol VISTA)

2004 - Principal Investigator - Eyetech - A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreal Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to CRVO (Protocol EOP 1011B)

2004 - Principal Investigator - Eyetech - A Phase II Prospective, Randomized, Double-Masked, Sham-Controlled, Dose-Ranging, Multi-Center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD) (Protocol EOP 1009)

David M. Brown MD FACS

Page 47

2004 - Principal Investigator - NEI/Emmes - The Standard Care vs. Corticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema (Protocol SCORE)

2005 - Principal Investigator - Alcon - Anecortave Acetate Risk-Reduction Trial: Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Singaporean Patients at Risk for Progressing to Exudative Age-Related Macular Degeneration (Protocol AART C-04-30)

2004 - Principal Investigator - NEI /Jaeb Center for Health/DRCR.net - A Phase III Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema (Protocol B)

2003 - Principal Investigator - Chromaderm / Eli Lilly- A Phase III Study of the Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema (Protocol Lilly 5882 B7A-MC-MBCU)

2003 - Principal Investigator - NEI /Jaeb Center for Health Research/DRCR.net - A Phase II Pilot Study of Laser Photocoagulation for Diabetic Macular Edema (Protocol A)

2003 - Principal Investigator - QLT/Novartis - Visudyne Minimally Classic (VMC) trial

2003 - Principal Investigator - Eyetech - Clinical trial for predominantly classic CNVM secondary to ARMD (Protocol Macugen EYE1008)

2003 - Principal Investigator - Genentech - A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration (Protocol ANCHOR FVF2587g)

2003 - Principal Investigator - Genentech - A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration (Protocol MARINA FVF2598g)

2000 - Principal Investigator - Novartis - Visudyne phase IV clinical trial

1995 - Sub-Investigator - Ionis - Phase II Open-Label Study of the Safety and Efficacy of Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients With Cytomegalovirus Retinitis (Protocol ISIS 2922-CS7)

David M. Brown MD FACS

Page 48